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Hypocretin 1 and 2 (HCRT, also called Orexin A and B) are neuropeptides released 
by neurons in the lateral hypothalamus. HCRT neurons widely project to the entire 
neuroaxis, excluding cerebellum (Peyron 1998). HCRT have been reported to 
participate in, or have an influence on, various physiological processes including 
cardiovascular functions (Shirasaka 1999), behavior (Ida 1999), wake-sleep cycle 
(Sakurai 2007), and they may also influence metabolic rate (Lubkin 1998) and the 
regulation of  body temperature (Balaskò 1999). These physiological processes are 
strongly interrelated and the hypothalamus plays a critical role in the control of them. 
HCRT neurons are lost in narcolepsy, a rare (prevalence 1:2000), debilitating 
neurological disorder,  characterized by excessive daytime sleepiness, cataplexy, 
sleep fragmentation and occurrence of sleep-onset rapid-eye movement episodes 
(SOREMPs), (Bassetti 2005). 
In narcoleptic patients, thermoregulatory cardiovascular control is impaired 
(Fronczek 2006), and it has been suggested that the related core body temperature 
and skin temperature alterations might causally affect vigilance and sleepiness in 
these patients (Fronczek 2008a). Furthermore, loss of HCRT neurons is often 
accompanied by defective energy and metabolic homeostasis, including a high risk 
for obesity (Kok 2003; Hara 2005) and the potential for altered thermoregulation 
(Plazzi 2011). 
I investigated whether HCRT neurons mediate the sleep-dependent cardiovascular 
adaptations to changes in ambient temperature (Ta). Cardiovascular regulation is 
affected by Ta especially in small animals such as rodents (Swoap 2004). Ambient 
temperature also influences cardiovascular regulation in humans and it has been 
demonstrated that the exposure to cold environment is involved in coronary heart 
disease occurrence (Danet 1999). 
Narcoleptic mice with genetic ablation of HCRT neurons (n=11) and wild-type 
controls (n=12), both with mixed genetic background, were implanted with a 
telemetric blood pressure transducer and electrodes to discriminate wake-sleep 
behavior. HCRT-ataxin-3 transgenic mice, with a mixed genetic background (75% 
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C57Bl/6J-25% DBA/2J) are more sensitive to the development of metabolic 
alterations than narcoleptic mice with a pure genetic background (Hara 2005). Thus, 
in order to better identify imbalances in metabolic homeostasis, experiments were 
performed on hybrid mice. Recordings were performed in each mouse at ambient 
temperatures of 25°C (acclimation temperature), 30°C, and 20°C in random order. 
Mean blood pressure (MBP) and heart rate (HR) were computed in each wake-sleep 
behavior and analyzed with 3-way analysis of variance and t-tests (significance at p < 
0.05). Results revealed a significance of the main effects of wake-sleep state and Ta, 
their interaction effect, and the wake-sleep state x mouse strain interaction effect on 
MBP and HR in both mouse strains, with MBP and HR increased with Ta decreasing. 
This effect of Ta on BP was significantly lower in rapid-eye-movement sleep 
(REMS) than either in non-rapid-eye-movement sleep (NREMS) or wakefulness (W) 
regardless of the mouse strain. MBP and HR were higher in W than either in NREMS 
or REMS. This effect of sleep on BP was significantly reduced in mice lacking 
HCRT neurons at each Ta, both in the dark and light periods, and particularly during 
REMS. These data suggest that HCRT neurons play a critical role in mediating the 
effects of sleep but not those of Ta on MBP and HR in mice. HCRT neurons may 
thus be part of the central neural pathways that mediate the phenomenon of blood 
pressure dipping on passing from wakefulness to sleep. Several studies have revealed 
an association between non-dipping BP profile and increased cardiovascular risk. 
This concept may have clinical implications in patients with narcolepsy with 
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1.1 Hypocretin/orexin system: anatomy 
and function 
Hypocretin 1 and 2 (HCRT-1, HCRT-2), also called orexin A and B, are 
neuropeptides produced by neurons in the lateral and posterior hypothalamus (De 
Lecea 1998; Sakurai 1998). 
In 1998 two research groups, using different techniques, independently discovered 
these neuropeptides and named them differently. Sakurai et al. called them orexins, 
whereas De Lecea et al. called them hypocretins. 
Sakurai et al. undertook a systematic biochemical search for endogenous peptide 
ligands for multiple orphan G-protein-coupled cell surface receptors (GPCRs), using 
a cell-based reporter system. These screening experiments led to the identification of 
a novel family of neuropeptides that bind to two closely-related orphan GPCRs. 
These peptide ligands were called “orexins,” after the Greek word orexis, which 
means appetite. The mRNA for the precursor of these peptides was found to be 
abundantly and specifically expressed in the lateral hypothalamus and adjacent areas, 
a region classically implicated in the central regulation of feeding behavior and 
energy homeostasis. In fact, when administered centrally in rat brains these 
neuropeptides stimulated food consumption and their production was influenced by 
the nutritional state of the animal (Sakurai 1998). 
de Lecea et al. identified Clone 35 among 38 c-DNA clones of m-RNA specifically 
expressed in the hypothalamus. This clone was expressed in the posterior 
hypothalamus and encoded the precursor of two putative peptides, the hypocretins, 
which shared substantial amino acid identities with each other and with the gut 
hormone secretin. The HCRT mRNA, which accumulated primarily after postnatal 
week 3 and was a product of a gene on chromosome 11 in mice, was restricted to 
neuronal cell bodies of the dorsal and lateral hypothalamus (De Lecea 1998). 
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To avoid confusion, the hypocretin nomenclature is used throughout this script, but it 
should be noted that the names “orexin” and “hypocretin” are currently used 
synonymously in many papers. 
 
HCRT-1 is a 33-amino acid peptide of 3,562 Da with an amino (N)-terminal 
pyroglutamyl residue, two intra-chain disulphide bonds and carboxy (C)-terminal 
amidation. This structure is completely conserved among several mammalian species 
(human, rat, mouse, cow, sheep, dog and pig). HCRT-2 is a 28-amino acid C-
terminally amidated linear peptide of 2,937 Da. The C-terminal half of HCRT-2 is 
very similar to that of HCRT-1, whereas the N-terminal half is more variable. HCRT-
2 is 46% identical to HCRT-1 (Sakurai 2007). Human HCRT-2 has two amino acid 
substitutions compared to the rodent sequence within the 28-residue stretch. The 
HCRT-2 found in pigs and dogs has two amino acid substitutions compared to human 
and rodent sequences. HCRT-1 and 2 are derived from a common precursor peptide, 
prepro-hypocretin (prepro-HCRT) polypeptide. An mRNA encoding the same 
precursor peptide was independently isolated as a hypothalamus-specific transcript. It 
was predicted that the transcript encoded a polypeptide precursor which is cleaved to 
form two neuropeptides. The prepro-HCRT gene encodes for a 130-residue (rodent) 
or 131-residue (human) polypeptide (Sakurai 1999). Human prepro-HCRT gene is 
localized on chromosome 17q21, which corresponds to chromosome 11 in the mouse. 
The prepro-HCRT gene consists of two exons and one intron distributed over 1432 
base pairs. The 143-base pair first exon includes the 5’-untranslated region and a 
small part of the coding region that encodes the first seven residues of the secretory 
signal sequence. The second exon contains the remaining portion of the open reading 
frame and 3’-untranslated region. The gene contains only one intron which is 818 bp 
long. A fragment of human prepro-HCRT gene, which contains a 3.15-kb 5’-flanking 
region and the whole length of the 5’-noncoding region of exon 1 is sufficient to 
direct the expression of the Escherichia coli β-galactosidase (lacZ) gene in HCRT 
neurons without ectopic expression in transgenic mice. The lacZ-positive neurons 
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were positively stained with anti-HCRT antibody suggesting that this genomic 
fragment contains all the necessary elements for appropriate expression of the gene 
(Ohno 2008). 
This fragment of the human prepro-HCRT gene, functioning as a promoter, is useful 
for examining the consequences of expression of exogenous molecules in HCRT 
neurons of transgenic mice, thereby manipulating the cellular environment in vivo. 
For example, this promoter was used to establish several transgenic lines, including 
HCRT neuron-ablated mice and rats (Hara 2001) in which HCRT neurons 
specifically express green fluorescent protein (Yamanaka 2003) or calcium-sensitive 
fluorescent protein (yellow cameleon Yc2.1). 
 
The actions of hypocretins are mediated by two receptors, named hypocretin 1 
receptor (HCRT-1R) and hypocretin 2 receptor (HCRT-2R). 
Among various classes of G protein-coupled receptors, HCRT-1R is structurally 
similar to certain neuropeptide receptors, most notably to the Y2 neuropeptide Y 
(NPY) receptor (26% similarity), followed by the thyrotropin-releasing hormone 
(TRH) receptor, cholecystokinin type-A receptor and NK2 neurokinin receptor (25%, 
23%, and 20% similarity, respectively). 
There is a 64% amino acid identity between the deduced full-length human HCRT-
1R and HCRT-2R sequences. Thus, these receptors are much more similar to each 
other than they are to other GPCRs. The amino acid identity between the human and 
rat homologues of each of these receptors is 94% for HCRT-1R and 95% for HCRT-
2R, indicating that both receptor genes are highly conserved between the species. 
Competitive radioligand binding assays suggested that HCRT-1 is a high-affinity 
agonist for HCRT-1R. The concentration of cold HCRT-1 required to displace 50% 
of specific radioligand binding (IC50) was 20 nM. Human HCRT-2 also acted as a 
specific agonist on HCRT-1R. However, human HCRT-2 has significantly lower 
affinity compared to human HCRT-1: the calculated IC50 in competitive binding 
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assay was 250 nM for human HCRT-2, an affinity which was two orders of 
magnitude lower, compared to HCRT-1. 
On the other hand, binding experiments demonstrated that HCRT-2R is a high-
affinity receptor for human HCRT-2 with IC50 of 20 nM. HCRT-1 also had high 
affinity for this receptor with IC50 of 20 nM, which is similar to the value for HCRT-
2, suggesting that HCRT-2R is a non-selective receptor for both HCRT-1 and HCRT-
2 (Ohno 2008). 
Both HCRT-1R and HCRT-2R are G protein-coupled receptors, which transmit 
information into cells by activating heterotrimeric G proteins. Activation of the 
signaling pathways associated with distinct G proteins may contribute to the diverse 
physiological roles of HCRT in particular neurons. 
Although many G protein-coupled neurotransmitter receptors are potentially capable 
of modulating both voltage-dependent calcium channels and G protein-gated 
inwardly rectifier potassium channels (GIRKs or Kir3 channels), there might be a 
substantial degree of selectivity in the coupling to one or another of these channels in 
neurons. 
HCRT-1R is thought to transmit signals through the Gα11 class of G protein, which 
results in the activation of phospholipase C with subsequent triggering of the 
phosphatidylinositol cascade and influx of extracellular Ca2+. HCRT-2R is thought to 
be coupled to both Gα11 and inhibitory Gi G proteins (Zhu 2003). 
HCRT-1R and HCRT-2R mRNAs exhibit a markedly different and basically 
complementary distribution, indicating that these receptors have distinct 
physiological roles (Marcus 2001). HCRT-1R mRNA was observed in many brain 
regions including the prefrontal and infralimbic cortex, hippocampus, paraventricular 
thalamic nucleus, ventromedial hypothalamic nucleus, dorsal raphe nucleus, and 
locus coeruleus. HCRT-2R mRNA was prominent in a complementary distribution 
including the cerebral cortex, septal nuclei, hippocampus, medial thalamic groups, 
raphe nuclei, and many hypothalamic nuclei including the tuberomammillary 
nucleus, dorsomedial nucleus, paraventricular nucleus, and ventral premammillary 
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nucleus. The differential distribution of HCRT receptors is consistent with the 
proposed multifaceted roles of hypocretins (Marcus 2001). 
 
HCRT neurons originate in the hypothalamus and are localized in the lateral and 
posterior hypothalamus (Peyron 1998). These neurons are variable in size (the cell 
body diameter ranges from 15–40 µm) and shape (spherical, fusiform or multipolar), 
and have been assumed to number around 3000 in the rat brain, or 7000 in the human 
brain (Peyron 1998; Nambu 1999). From these regions, HCRT neurons project 
widely to the entire neuroaxis, excluding the cerebellum.  
Hypocretins were recognized as regulators of feeding behaviour, firstly because of 
their exclusive production in the lateral hypothalamic area (LHA), a region known as 
the feeding centre, and secondly owing to their pharmacological activity. 
The finding that prepro-HCRT RNA and HCRT immunoreactive cells were localized 
in a sub-region of the dorsolateral hypothalamus and the co-localization of HCRT 
with melanin-concentrating hormone (MCH), which is considered an orexigenic 
peptide, suggested a possible role of HCRT in the regulation of feeding behavior. 
Intracerebroventricular (ICV) injection of HCRT during the light period induces 
feeding behaviour in rats and mice (Sakurai 1999). 
HCRTs also have a crucial role in regulating sleep and wakefulness; accordingly, the 
deficiency of these hypothalamic neuropeptides causes narcolepsy in humans and 
animals. The possible involvement of the HCRT system in the regulation of 
wakefulness and sleep was first noted in experiments performed on animal models of 
HCRT deficiency. 
Different animal models of narcolepsy, with HCRT transmission deficiency, have 
been studied. These models include prepro-HCRT gene or HCRT-2R gene knockout 
mice, double receptor-1 and receptor-2 knockout mice, and hypocretin-ataxin-3 
transgene-induced loss of HCRT neurons in rats and mice (Hara 2001; Willie 2003). 
In 1999,  Lin et al. discovered a mutation in the gene coding for the HCRT-2R as the 
cause of familial canine narcolepsy (Lin 1999). In the same year, a study involving 
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behavioral and electroencephalographic criteria by Chemelli et al. reported that 
HCRT knockout mice exhibited a phenotype that was strikingly similar to human 
narcolepsy patients, as well as canarc-1 mutant dogs, the only known monogenic 
model of  narcolepsy (Chemelli 1999). 
Narcolepsy is a disabling sleep disorder characterized by excessive daytime 
sleepiness and abnormal rapid-eye-movement (REM) sleep manifestations including 
cataplexy (sudden loss of muscle tone triggered by strong emotions), sleep paralysis, 
and hypnagogic (sleep-onset) hallucinations and sleep onset REMS periods 
(Scammell 2003). 
In the following paragraphs, I will sum up the role of HCRT in the regulation of 
physiological functions: wake-sleep behavior, cardiovascular regulation, regulation of 
energy metabolism and body temperature, and respiratory control. 
 
1.1.1 Hypocretins and wake-sleep behavior 
It has been shown that in rats ICV injection of HCRT-1 or 2 during the light (rest) 
period, the equivalent of night-time in humans, increases awake time and decreases 
REM and NREM sleep time (Bourgin 2000), (ref. 3.1.1 for more detailed information 
regarding sleep characteristics). 
HCRT neurons project widely to the entire neuroaxis, excluding the cerebellum. The 
densest staining of HCRT-immunoreactive nerve endings in the brain is found in the 
paraventricular nucleus of the thalamus, the arcuate nucleus and, most notably, the 
locus coeruleus (LC, containing noradrenergic neurons), dorsal raphe (DR, which 
contains serotonergic neurons) and tuberomammillary nucleus (TMN, containing 
histaminergic neurons), (Nambu 1999; Peyron 2000). The distribution of mRNA for 
the HCRT receptors is consistent with these projection sites; within the brain, HCRT-
1R mRNA is most abundantly expressed in the LC, whereas HCRT-2R mRNA is 
highly expressed in the TMN (Marcus 2001). Both regions are important for the 
maintenance of arousal. The DR and ventral tegmental area (VTA) contain both 
HCRT-1R and HCRT-2R mRNA (Marcus 2001). These observations indicate that 
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these monoaminergic regions are important effector sites of hypocretins, involved in 
increasing arousal and promoting wakefulness (Sakurai 2007). Consistent with this 
hypothesis, electrophysiological experiments using brain slice preparations or 
isolated cells have shown that cells of these nuclei are activated by hypocretins in 
vitro. Indeed, noradrenergic cells of the LC, dopaminergic cells of the VTA, 
serotonergic cells of the DR, and histaminergic cells of the TMN have all been shown 
to be activated by hypocretins (Liu 2002; Yamanaka 2002). 
The activity of monoaminergic neurons in the TMN, LC and DR is known to be 
synchronized and strongly associated with sleep and wakefulness: the neurons fire 
tonically during wakefulness, less during NREMS, and stop firing during REMS. 
These observations indicate that HCRT-mediated arousal results from the activation 
of these wake-active monoaminergic neurons. Specifically, HCRT neurons, activated 
during wakefulness, exert an excitatory influence on these wake-active neurons, 
thereby sustaining their activity. HCRT neurons need to be switched off in order to 
maintain consolidated NREMS and the muscle atonia that accompanies REMS, but 
have to be activated during the awake period (Sakurai 2007). Lee et al. found that the 
HCRT neurons fired during active waking, decreased discharge during quiet waking, 
and virtually ceased firing during both REMS and NREMS. HCRT neurons increased 
their firing before the end of REMS and thereby heralded the return of the awake 
state by several seconds. Although the numbers of cells examined are too small to 
provide a complete picture of HCRT neurons activity across the sleep–wake cycle, 
these seminal studies provide the strongest evidence that these cells are activated 
during wakefulness, and inhibited during sleep (Lee 2005). 
HCRT neurons interact with the neuronal system and these interactions provide a key 
to understanding the physiological roles of these neurons. They receive inputs from 
the limbic system (Sakurai 2007). The  importance of this connection is readily 
apparent in the defense, or “fight or flight”, response: mice tested in a resident-
intruder paradigm show cardiovascular and locomotor responses to the emotional 
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stress evoked by this test, but these responses are diminished in prepro-HCRT 
knockout mice (Kayaba 2003). 
The neural input from the limbic system to HCRT neurons might be implicated in the 
pathophysiology of cataplexy, because strong, generally positive emotional stimuli 
are known to trigger cataplexy in narcolepsy-cataplexy patients (Sakurai 2007). 
HCRT neurons receive a lot of innervations from the suprachiasmatic nucleus (SCN) 
and the dorsomedial hypothalamus (DMH). This indicates that HCRT neurons might 
receive circadian influences indirectly from the SCN via these regions. 
The preoptic area, especially the ventrolateral preoptic area (VLPO), seems to have a 
crucial role in NREMS initiation and maintenance. Neurons in the VLPO fire at a 
rapid rate during sleep, with attenuation of firing during wakefulness. GABA and 
galanin are the primary inhibitory neurotransmitters of the VLPO, which sends out 
multiple inhibitory projections to the LC, TMN and DR. 
HCRT neurons are innervated by GABA-containing cells in the VLPO (Yoshida 
2006), indicating that the VLPO might be a source of GABA-containing inhibitory 
projections to HCRT neurons. This pathway might be important for turning off 
HCRT neurons during sleep. 
To explain how HCRT neurons stabilize sleep and wakefulness through the neural 
circuits discussed above, Saper et al. proposed that the HCRT system is part of a flip-
flop system. A “flip-flop switch”, a circuit containing mutually inhibitory elements, 
sets up a self-reinforcing loop, where activity in one of the competing sides shuts 
down inhibitory inputs from the other side, and therefore disinhibits its own action 
(Saper 2005).  
The “flip-flop switch” circuit is composed of the arousal system, which promotes 
wakefulness, and the VLPO, which promotes sleep.  
The arousal system consists of two major branches: the first is an ascending pathway 
to the thalamus that activates the thalamic relay neurons which project to the cerebral 
cortex. The major source of upper brainstem input to the thalamic-relay nuclei, as 
well as to the reticular nucleus of the thalamus, is a pair of acetylcholine-producing 
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cell groups: the pedunculopontine and laterodorsal tegmental nuclei (PPT/LDT), 
(Hallanger 1987). The neurons in the PPT/LDT fire most rapidly during wakefulness 
and REMS. These cells are much less active during NREMS, when cortical activity is 
slow. The second branch of the ascending arousal system bypasses the thalamus, 
instead activating neurons in the lateral hypothalamic area, and throughout the 
cerebral cortex. This pathway originates from monoaminergic neurons in the upper 
brainstem and caudal hypothalamus, including the noradrenergic LC, serotoninergic 
DR  and median raphe nuclei, dopaminergic ventral periaqueductal grey matter and 
histaminergic TMN (Saper 2001). 
On the other side of the circuit there is the VLPO. The VLPO neurons are primarily 
active during sleep, and contain inhibitory neurotransmitters, galanin and GABA. 
Experiments showed that cell-specific lesions of the VLPO reduce both NREMS and 
REMS by more than 50% (Lu 2000). 
The VLPO also receives inhibitory afferents from each of the major monoaminergic 
and histaminergic systems. Both noradrenaline and serotonin inhibit VLPO neurons.  
Therefore, the VLPO can be inhibited by the arousal systems that it inhibits during 
sleep (Saper 2005). 
To summarize, during wakefulness, HCRT neurons send excitatory influences to 
monoaminergic neurons, which send inhibitory feedback projections to HCRT 
neurons. This system might maintain the activity of monoaminergic neurons. A slight 
decrease in input to the monoaminergic neurons results in decreased inhibitory 
influence to HCRT neurons. HCRT neurons, therefore, are disinhibited and increase 
excitatory influence to monoaminergic cells to maintain their activity. These 
monoaminergic cells send excitatory projections to the thalamus and cerebral cortex, 
and inhibitory projections to the VLPO sleep centre. These mechanisms maintain 
wakefulness. During sleep, VLPO sleep active neurons are activated and send 
inhibitory outputs to monoaminergic neurons and HCRT neurons in order to maintain 
sleep. In narcolepsy, when HCRT neurons are lacking, monoaminergic neurons and 
VLPO neurons set up a mutually inhibitory circuit, which can cause unwanted and 
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abrupt transitions between the states. Activity in one of the competing sides shuts 
down inhibitory inputs from the other side, and therefore disinhibits its own action. 
So, when either side begins to overcome the other, the switch abruptly turns into the 
alternative state (Sakurai 2007). 
 
1.1.2 Hypocretin and cardiovascular regulation 
Behavioral activities such as exercise, fighting and food-seeking must be faced by the 
organism with an integrated response. Such a response is based on coordinated 
hypothalamic activation of somatomotor, hormonal and autonomic pathways. 
Accordingly, cardiovascular adaptative responses are mediated by different 
hypothalamic neuropeptides. HCRT containing-neurons and their receptors are 
distributed in brain regions closely associated with the regulation of cardiovascular 
and autonomic function. HCRT receptor mRNA is expressed in the hypothalamic 
paraventricular nucleus (PVN), which is involved in the integration of the autonomic 
nervous and neuroendocrine systems. 
The pre-autonomic parvocellular neurons of the PVN send long descending 
projections to several areas within the CNS that are known to be important in 
cardiovascular function. These regions include the nucleus of solitary tract (NTS), 
where baroreceptor and chemoreceptor afferents terminate, the dorsal vagal complex, 
which is present in the dorsomedial medulla and contains vagal preganglionic 
neurons, the rostral ventrolateral medulla (RVLM), which is probably a major site for 
the generation of sympathetic tone for the vasculature, and the intermediolateral 
column of the spinal cord, which is the site of sympathetic preganglionic motor 
neurons involved in the regulation of blood pressure (BP) and heart rate (HR) 
(Shirasaka 2003). 
Through these pathways hypocretins may modulate cardiovascular adjustment to 
different motivated behavior, modulating sympathetic activity. 
Functional studies have shown that these peptides evoke changes in cardiovascular 
and sympathetic responses. The in vivo and in vitro studies suggest that the peptide 
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acting on neurons in the hypothalamic PVN increases the cardiovascular responses 
(Shirasaka 2002). Shirasaka et al. used conscious, freely moving rats to investigate 
the effect of ICV-administered hypocretins on mean arterial pressure (MAP), heart 
rate (HR), and sympathetic nerve activity. 
Intracerebroventricular administration of 0.3-nmol HCRT-1 and 2 significantly 
increased MAP but not HR in conscious rats (Shirasaka 1999). A higher dose (3.0 
nmol) of HCRT-1 and 2 rapidly increased MAP and HR, which reached a peak value 
within 15 min after injection. However, increases in MAP and HR were also 
observed in anesthetized rats, indicating that these responses were not due to 
increases in locomotor activities, such as chewing and grooming. Intravenous (IV) 
administration of hypocretins (11 nmol/kg) did not affect blood pressure and heart 
rate. These results indicate that hypocretins produce pressor and tachycardic 
responses by acting centrally. 
The high dose of HCRT-1 additionally resulted in an 60% increase in renal 
sympathetic nerve activity (RSNA) 10 min after injection, which persisted for 15 
min. RSNA also increased transiently at a low dose (0.3 nmol) of HCRT-1 but this 
increase was significantly lower than at 0.3 nmol (Shirasaka 1999). 
Central HCRT-2 also produced a significant increase in MAP, with a 10.8 ± 0.2 
mmHg increase at the high dose, this response pattern being similar to what was 
observed for HCRT-1 administration. HR also rapidly increased and returned to the 
control level within 30 min at 3.0 nmol. In contrast with the results obtained for 
HCRT-1, RSNA did not increase significantly at any dose of HCRT-2 (Shirasaka 
1999). 
To examine systemic sympathetic outflow induced by central hypocretins, plasma 
catecholamines were measured. High doses of HCRT-1 and 2 increase plasma 
norepinephrine (NE), the effect being larger and longer-lasting with HCRT-1. 
Therefore, it is likely that the HCRT-induced increase in sympathetic nerve outflow 
leads to the increase in plasma NE, which in turn induces cardiovascular responses. 
ICV-administered HCRT-1 also significantly increases plasma epinephrine (EP) 
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levels 10 min after injection (Shirasaka 2003). Central HCRT-1 infusion induces face 
washing behavior and grooming (Ida 1999), which is known to be related to a stress 
response. Stress has been reported to cause an increase in sympathetic nerve activity. 
Shirasaka et al. reported increases produced by central HCRT-1 administration in 
RSNA and plasma catecholamines, compatible to stress response. Moreover they 
demonstrated that central HCRT-1 at lower doses selectively causes the activation of 
RSNA, thus suggesting that HCRT-1 may be involved in renal excretory function 
through RSNA. Therefore, hypocretins may be involved in the central control of 
multiple homeostatic functions regulating sympathetic nerve activity. The role of 
HCRT in stress response has been widely examined. The defense response is 
characterized by increases in BP, HR, respiratory frequency, and resistance in 
visceral vascular beds, and by decreases in resistance in the airways and the skeletal 
muscle vascular bed. 
The defense response elicited by stimulation of the hypothalamic perifornical area 
(PFA) is attenuated in genetically engineered mouse models of hypocretin deficiency. 
These mice show an attenuated response to emotional stressors with blunted increases 
in BP, HR and locomotor activity (Kayaba 2003). 
The contribution of HCRT to the multiple efferent pathways of the defense response 
was investigated by stimulating PFA of HCRT knockout mice and HCRT-ataxin-3 
transgenic mice. The aim was to verify the involvement of HCRT in determining all 
the features of the defense response. 
As expected, bicuculline stimulation of PFA, increases in BP, HR, respiratory 
frequency, and h-band power of electroencephalogram (an index of cortical arousal) 
were smaller and/or shorter-lasting in HCRT knockout mice than in WT littermates.  
In a similar manner, increases in BP, HR, and respiratory minute volume and 
vascular dilatation in skeletal muscle were attenuated in HCRT-ataxin-3 transgenic 
mice (Zhang 2006). Therefore, HCRT-containing neurons in the PFA play a role as a 
master switch to activate multiple efferent pathways of the defense response.  
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HCRT but not co-transmitters (glutamate, dinorphin and galanin) in the neurons 
seemed to be important at least for the changes in BP, HR, and respiration in the 
defense response considering the similarity in the examined parameters between the 
two animal models included in the experiments (Zhang 2006). 
This, however, was not true of co-transmitters (glutamate, dinorphin and galanin). 
Data regarding the role of HCRT in cardiovascular regulation are still conflicting. 
Recent studies suggest a bidirectional dose-dependent cardiovascular response to 
microinjection of HCRT in the NTS (Shih 2007). 
In particular, at a lower dose (5 pmol), HCRT-1 and 2 decreased arterial pressure, 
HR, and power density of the vasomotor components of BP signals, an experimental 
index for sympathetic neurogenic vasomotor tone. At higher doses (>20 pmol), these 
two compounds elicited cardiovascular excitatory responses (Shih 2007). Hypocretins 
probably exert their effects through activation of the nitric oxide (NO) synthase. 
Depending on the amount, NO exerts differential cardiovascular responses. In the 
NTS low and high concentrations of NO entail differential modulation of 
glutamatergic and GABAergic synaptic transmission. At a low level, NO potentiates 
glutamatergic excitatory postsynaptic potentials whereas at a high level it augments 
monosynaptic GABAergic inhibitory postsynaptic potentials (Wang 2007). So at a 
low dose HCRT activates NO synthase to generate a low level of NO, thus leading to 
vasodepression, while at a high dose HCRT induces a greater production of NO, 
which activates the GABAergic neurotransmission and overrides cardiovascular 
inhibition to yield excitation. If  HCRT receptor antagonists are administered, these 
bidirectional cardiovascular effects are abolished (Shih 2007). 
These results were confirmed by other experiments performed in order to evaluate the 
dose-dependent effect of IV or ICV injection of various doses of HCRT-1 on RSNA 
and BP. Tanida et al. found that injection of a low dose of HCRT-1 (10 ng IV or 0.01 
ng ICV) suppressed RSNA and BP significantly. Conversely, a high dose (1000 ng 
IV or 10 ng ICV) elevated both RSNA and BP (Tanida 2006). 
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Furthermore, bilateral lesions of the hypothalamic suprachiasmatic nucleus (SCN) 
abolished the effects of both low and high doses of HCRT-1 on RSNA and BP. These 
findings suggest that HCRT-1 affects RSNA and BP in a dose-dependent manner and 
that the SCN may modulate this effect. In rats, the hypothalamic SCN, in addition to 
functioning as a master circadian oscillator, is involved in the control of BP through 
autonomic nerves to sympathetic and parasympathetic neurons modulating BP. 
Through their projections to the NTS, RVLM, VMMR, DMN, and intermediolateral 
column of the spinal cord, HCRT neurons may modulate cardiovascular adjustments 
to different motivated behaviors (Tanida 2006). In conscious rabbits, ICV injection of 
HCRT-1 elicited a dose-dependent increase in mean BP and RSNA; it also increased 
plasma epinephrine and vasopressin concentrations (Matsumura 2001). The effect of 
microinjections of HCRT-1 into the rostral ventromedial medulla (RVMM) of rats 
elicited a dose-dependent increase in HR with little or no change in MAP, thus 
activating neuronal circuits that both inhibit vagal activity and increase sympathetic 
activity to the heart (Ciriello 2003). 
Chronic ICV infusion of HCRT-1 (50 pmol/h) elicited a significant increase in 
systolic blood pressure on the third day (+15.6  2.9 mmHg), and during the 
continuous ICV infusion of HCRT-1, BP returned to the baseline levels at day 14. 
These results suggest that central HCRT-1 participates in the short-term regulation of 
blood pressure; however, the contributions of central hypocretins to the long-term 
regulation of blood pressure, sympathetic nervous system, and appetite may be minor 
(Lin 2002).  
Results obtained from studies performed in narcoleptic patients regarding the role of 
hypocretins in cardiovascular control are not in full agreement with those obtained in 
animals.  
Firstly in 1982, Sachs and coll. described the presence of an impaired autonomic 
control in narcoleptic patients (Sachs 1982). This study evaluated autonomic 
cardiovascular responses of narcoleptic patients to specific tests: 1) heart rate and 
blood flow in the resting forearm during contralateral isometric handgrip, 2) 
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respiratory sinus arrhythmia, and  3) heart rate response to the Valsalva maneuver. 
They found that autonomic cardiovascular reflexes, such as the diving reflex (in 
which bradycardia is elicited by an increase in vagal activity) and the orthostatic test 
(in which an increase in BP depends mainly on sympathetic vasoconstriction) were 
similar in narcoleptic patients and controls, indicating intact peripheral nerves. On the 
contrary, the controlateral isometric handgrip test (in which an increase in blood flow 
is mediated by β-adrenergic vasodilatation and an increase in HR depends on the 
inhibition of vagal efferent) highlighted reduced responses in narcoleptic patients. 
Vagal activity was evaluated measuring the respiratory sinus arrhythmia (RSA) and 
HR responses to the Valsalva maneuver (in which patients maintain a constant 
expiratory rate by blowing through a mouthpiece that permits a slow air flow). The 
results demonstrated an attenuated reactivity in the vegetative control system of 
narcoleptic patients. These findings suggested a central origin of the autonomic 
imbalance (Sachs 1982). Unfortunately, these results were not confirmed later by 
other studies. In 1994, Hublin et al. measured BP and HR changes during the deep 
breathing test, Valsalva test and Orthostatic test. No significant differences between 
narcoleptic patients and control subjects were found (Hublin 1994). More recently, 
Grimaldi et al. found normal functioning of cardiovascular reflexes in narcoleptic 
patients, but an impairment of HR modulation at rest with enhanced sympathetic 
activity (Grimaldi 2010a). 
In 1986, Baker et al. reported that narcoleptic patients tended to have higher BP 
values (Baker 1986), without taking into account the effect of sleep on BP. Instead, 
Guillemineault found that in narcoleptic patients there was no difference in the blood 
pressure measurements throughout the night compared with normal control subjects 
(Guilleminault 1986).  
Ferini-Strambi et coll. excluded primary disturbances of the cardiac autonomic 
control in narcolepsy, finding a higher sympathovagal balance in patients compared 
to controls during wakefulness before sleep. They ascribed this result to an attenuated 
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activation of the parasympathetic system, probably due to the wake-sleep cycle 
impairment in narcoleptic patients (Ferini-Strambi 1997).  
Fronczek et al.  hypothesized a reduced sympathetic tone in patients, even if mean 
HR did not differ between the groups (Fronczek 2008b ). Conversely, when studying 
HR variability in the supine rest condition, a recent study  showed significantly 
higher HR values in narcoleptic patients than in controls. Authors suggested that this 
may reflect an increased sympathetic drive, or alternatively a reduced 
parasympathetic drive on HR in narcoleptic patients (Grimaldi 2010b). The variable 
results of these studies emphasize the insufficiency of single assessments of the 
autonomic nervous system during wakefulness and probably reflect the insufficient 
standardization of test conditions. 
In order to find a unifying position as to whether HCRT deficiency involves 
autonomic cardiovascular impairment in narcoleptic patients, it is important to take 
into account the abnormal wake-sleep behavior often associated with narcolepsy. 
The nighttime sleep of narcoleptic patients is unstable, with frequent stage shifts, 
arousals and increased motor activity during sleep such as periodic leg movements in 
sleep (PLMS), (Dauvilliers 2007). PLMS consists of sudden jerking movements of 
the legs which occurring involuntarily during sleep, during which the affected 
individual may remain unaware. It may involve kicking, twitching, or extension of 
the legs. It tends to increase with age and often accompanies restless leg syndrome 
(RLS). PLMS during sleep are frequently associated with arousals and awakenings. 
Narcoleptic patients have a higher frequency of PLMS than controls, especially 
during REMS. Interestingly, it has been reported that in narcoleptic patients PLMS 
during sleep may be associated with huge increases in BP (Ali 1991).  
 
1.1.3 Hypocretin: feeding behavior and energy homeostasis 
Feeding behavior is dependent upon the integration of metabolic, autonomic, 
endocrine, and environmental factors coordinated with an appropriate state of cortical 
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arousal (wakefulness). Historically, it has been recognized that the hypothalamus 
plays a critical role in maintaining energy homeostasis by integrating these factors 
and coordinating behavioral, metabolic, and neuroendocrine responses (Willie 2001). 
In mammals, the neurons of the lateral hypothalamic area (LHA) are particularly 
important for feeding and behavioral arousal. Animal models with lesions of the LHA 
exhibit hypophagia, an increased metabolic rate and decreased arousal that frequently 
leads to death by starvation. Therefore, the LHA has classically been regarded as the 
hypothalamic “feeding center” and an important component of the autonomic 
nervous system with extensive projections within the hypothalamus and throughout 
the entire neuroaxis (Willie 2001). 
The striking localization of HCRT-containing neurons in the lateral hypothalamus 
and some of its adjacent areas suggests the possibility that the neuropeptide may be 
involved in the regulation of food intake and energy metabolism, and animal studies 
confirm the involvement of HCRT neurons in these kind of  regulations. 
Sakurai et al. administered HCRT acutely into the  lateral ventricle of male rats. In 
rats, acute ICV HCRT-1 injection during the early light phase produces a dose-
dependent manner increase in food consumption within 1 hr (6- and 10-fold increase 
for 3nmol and 30nmol, respectively), (Sakurai 1998). Consistent with the dense 
projections of HCRT neurons to the hypothalamic arcuate nucleus (ARC), (Peyron 
1998) several studies have suggested that the increased food intake following HCRT-
1 administration is at least in part mediated by the activation of neuropeptide Y 
(NPY) neurons in the ARC (Yamanaka 2000). The ARC is an important station of 
pathways that generate integrated responses to afferent information on fuel stores. 
Reciprocal connections between HCRT neurons and neurons located in the ARC, 
NPY/AgRP (Agouti related peptide), which are orexigenic peptides, and POMC 
(propiomelanocortin)/CART (cocaine-amphetamine-regulated transcript), which are 
anorexigenic peptides, provide an indirect regulation of HCRT neurons by leptin and 
ghrelin, indicators of the metabolic status. Leptin is produced by adipose tissue 
proportionally with the fat mass. High leptin levels suppress HCRT expression and 
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inhibit HCRT neuron firing. Ghrelin, a hormone secreted by the stomach prior to 
meals and during fasting, directly activates HCRT neurons. Finally, HCRT neurons 
may play an important role in sustaining the phenomenon of hypoglycemia 
awareness, in which low glucose levels trigger autonomic and behavioral activation 
and may cause awakening from sleep. Elevated glucose concentrations induce 
hyperpolarization and cessation of action potentials in HCRT neurons (Yamanaka 
2003). Supporting the physiological relevance of HCRT in the control of feeding, 
ICV administration of an anti-HCRT antibody or an HCRT-1R-selective antagonist 
has been showed to reduce food intake, and prepro-HCRT knockout mice and 
transgenic mice lacking HCRT neurons ate less than control wild-type mice (Hara 
2001).  
The LHA is also important in controlling metabolic rate. Animal models with lesions 
in the LHA consistently become hypercatabolic and remain so, even after they reach 
a lower body weight set-point. Conversely, the finding of decreased food intake and 
normal body weight suggests that HCRT knockout mice are likely to be 
hypometabolic. This hypothesis is supported by experiments performed by Lubkin & 
Stricker-Kongrad (Lubkin 1998). Using indirect calorimetry they found that HCRT-1 
injection during the light phase increases oxygen consumption and the respiratory 
quotient by an apparent increase in carbohydrate metabolism. A significant body of 
evidence has been accumulated for a role of hypocretins in the regulation of energy 
metabolism and autonomic function (Willie 2001). Besides increasing feeding 
behavior in a dose-dependent manner (Sakurai et al., 1998) and increasing oxygen 
consumption in mice indicating an increased metabolic rate (Lubkin 1998), 
hypocretins also have positive influences on the sympathetic outflow, as suggested by 
the increase in mean arterial BP and HR obtained in rats with HCRT administration 
into the lateral ventricle or ventrolateral medulla (Shirasaka 2002). These effects 
generally result in increased energy consumption.  
The role of hypocretins in energy homeostasis is confirmed by studies in animal 
models of narcolepsy. HCRT-ataxin-3 mice show late onset obesity, consistent with  
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human reports. However, food consumption in HCRT-ataxin-3 mice is decreased by 
almost 30% at 8 to 10 weeks of age, before obesity becomes apparent. Thus, reduced 
food intake is unlikely to be a compensation for increased weight gain. Rather, 
reduced feeding and obesity may together reflect a reduction in energy expenditure 
due to decreased motor activity, a lower basal metabolic rate, or both. A decreased 
spontaneous motor activity in the dark (active) period was observed in HCRT-ataxin-
3 mice. Decreased basal energy expenditure may result directly from the elimination 
of HCRT-containing neurons, which normally promote energy expenditure (Hara 
2001). 
The metabolic abnormality in HCRT-ataxin-3 mice seems more severe than that of 
prepro-HCRT knockout mice reported by Chemelli et al. (Chemelli 1999). These 
mice reportedly display normal growth rather than obesity, although they are also 
hypophagic. The observed metabolic differences between HCRT-ataxin-3 mice and 
prepro-HCRT knockout mice may stem from different genetic backgrounds and 
environmental effects. Loss of neuropeptides or modulatory factors expressed by 
HCRT-containing neurons may also contribute to phenotypic differences in these 
mice models. In particular, dynorphins, which influence feeding behavior, may play a 
role. Another intriguing possibility is that phenotypic differences result in part from 
fetal and/or early mouse postnatal development in the presence or absence of HCRT 
signaling in HCRT-ataxin-3 transgenic mice and knockout mice, respectively (Hara 
2001). 
Metabolic abnormalities in food intake and/or energy expenditure may affect 
narcoleptic patients. Narcoleptic patients have a decreased caloric intake but an 
increased body mass index, indicating that the abnormality that gives rise to 
narcolepsy has links to reduced energy expenditure or a low metabolic rate. This is 
suggested by increased frequencies of obesity and non-insulin-dependent (Type II) 
diabetes in narcoleptic patients compared with a control group (Schuld 2000). 
Recently, it has been demonstrated that narcoleptic patients show a high prevalence 
of metabolic syndrome. Several metabolic alterations are present in narcoleptic 
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patients, even though they show a significant reduction in food intake. The 
dysmetabolism is independent of BMI, and BMI is inversely associated with food 
intake: these data support the notion that the lack of HCRT may directly influence 
some metabolic parameters (Poli 2009). 
To summarize, the lack of HCRT leads to hypophagia, but also to late onset obesity, 
suggesting a separate effect of HCRT signaling on energy expenditure and feeding 
behavior. It has been shown that HCRT administration increases sympathetic 
outflow, with increased body temperature (Yoshimichi 2001), as well as increased BP 
and renal sympathetic nerve activity (Shirasaka 2002). Thus, lack of HCRT could 
result in reduced energy expenditure through decreased thermogenesis, and in obesity 
despite hypophagia. 
 
 1.1.4 Hypocretin and regulation of body temperature 
Maintenance of energy homeostasis depends on long-term and short-term regulatory 
processes. In the long-term, metabolic requirements must be met by proportional food 
intake; unbalanced intake-consumption produces changes in body weight. The short-
term balance between energy production (actual metabolic rate) and energy 
dissipation is a function of temperature regulation; any imbalance is manifested as 
change in body temperature (Székely 2002). 
Loss of HCRT neurons is often accompanied by defective energy and metabolic 
homeostasis, including a high risk for obesity (Kok 2003) and the potential for altered 
thermoregulation (Plazzi 2011).  
HCRT-containing fibers and HCRT receptors have been described in the rostral raphe 
pallidus region of the ventromedial medulla, the principal site of sympathetic and 
somatic premotor neurons for the regulation of thermal effectors (Morrison 2011). 
These neurons have a well-established role in the regulation of body temperature 
promoting brown adipose tissue (BAT) thermogenesis and cardiovascular adaptations 
to thermogenic needs (i.e., cutaneous vasoconstriction and increase in heart rate). 
Nanoinjection of orexin-A (12 pmol) into the rostral raphe pallidus, the site of BAT 
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sympathetic premotor neurons, produced large, sustained increases in BAT 
sympathetic outflow and in BAT thermogenesis (Tupone 2011). 
Moreover, HCRT neurons receive afferent projections from the pre-optic area (POA), 
and express c- Fos when muscimol (GABA-A agonist) is injected into the POA 
(Rusyniak 2011). These data, suggest that GABAergic neurons in the POA provide 
tonic inhibitory tone to HCRT-synthesizing neurons and that removing this tone 
contributes to an increase in body temperature, HR and BP (Satoh 2004).  
Many studies have explored the link between thermoregulation and HCRT. ICV 
infusion of HCRT-1 in rats causes an initial reduction of body temperature and 
metabolic rate, followed by a long-lasting hyperthermic period. On the contrary, 
HCRT-2 directly causes hyperthermia, without any metabolic changes (Székely 
2002). After the ICV injection of HCRT-1, rats show an increase in the firing rate of 
the sympathetic nerves projecting to interscapular BAT, in BAT and abdominal 
temperatures, and in HR. Thus, HCRT may regulate both BAT energy expenditure 
and thermogenesis through sympathetic nerve activity. A decreased sympathetic tone 
in absence of HCRT signaling could explain the increased fat accumulation and 
reduced energy expenditure (lower thermogenesis) described in narcolepsy (Plazzi 
2011). 
In narcoleptic patients the normal pattern of the circadian and state-dependent core 
body temperature cycle has been found to be preserved  (Grimaldi 2010a) or 
decreased (Fronczek 2008a). Fronczek et al., when studying skin temperature 
regulation in unmedicated narcoleptic patients throughout the day, reported an 
elevated distal skin temperature. In normal subjects, during daytime quiet 
wakefulness, distal skin areas are usually cooler than proximal ones, which is 
expressed as a negative distal- to-proximal gradient (DPG). The distal skin warms up 
when hypothalamic regulated sympathetic cutaneous vasoconstrictor tone is released, 
opening a dense network of arterio-venous anastomoses in the skin of the extremities. 
This vasodilatation seems to be correlated with sleep-onset. Experimentally-induced 
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changes in core body and skin temperature of narcoleptic patients seems to modify 
vigilance and sleepiness (Fronczek 2008a).  
Mockizucki et al. studied core body temperature (Tb) in HCRT knockout mice. These 
authors hypothesized that HCRT knockout mice would have a lower Tb compared to 
controls, due to their lower sympathetic vasoconstrictor tone. Moreover, because 
HCRT is released during wakefulness, they hypothesized that HCRT knockout mice 
would have lower Tb while awake. Surprisingly, Tb was the same in HCRT knockout 
mice and wild-type littermates during sustained wakefulness, whereas Tb of HCRT 
knockout mice fell much less steeply than normal during sleep. 
There are different possible explanations for these results. The first is that heat loss 
mechanisms might not be fully engaged in HCRT knockout mice thus accounting for 
the fact that Tb falls more slowly. It may also be that HCRT KO mice fall asleep 
without much activity in sleep-promoting preoptic neurons. Because these preoptic 
neurons also activate heat loss mechanisms, Tb falls less steeply during sleep. 
A second explanation is that HCRT deficiency may directly impair mechanisms that 
reduce Tb. Stimulation of the caudal lateral hypothalamus triggers tail vasodilation in 
rats and the lateral hypothalamic HCRT neurons may contribute to this response.  
Furthermore, the HCRT neurons project to many brain regions implicated in 
thermoregulation, including the preoptic area, dorsomedial hypothalamus, 
ventromedial hypothalamus, posterior hypothalamus, periaqueductal grey matter, 
medullary raphe, and intermediolateral cell column of the spinal cord (Peyron 1998; 
Marcus 2001; Berthoud 2005). These neurons work together to regulate Tb 
depending on physiological needs, and HCRT may be a key signal in the control or 
synchronization of the activity of these neurons. 
Finally, a third possibility is that the reduced fall in Tb could be caused by sustained 
thermogenic activity during sleep. HCRT deficiency may reduce sympathetic tone 
because HCRT knockout mice have lower blood pressure. If HCRT deficiency 
reduces sympathetic activity and locomotor activity during wakefulness, then other 
heat-generating mechanisms may compensate in order to produce normal Tb during 
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wake. Thermogenic endocrine signals might be upregulated to maintain heat 
production, normalizing Tb during wake, but producing an inappropriately high Tb 
during sleep (Mochizuki 2006). 
In conclusion, all these results indicate a potent modulation of body temperature by 
HCRT released from the terminals of HCRT neurons to the cerebral areas involved in 
thermoregulation and provide a potential mechanism contributing to the disrupted 
regulation of body temperature and energy metabolism as a consequence of HCRT 
signaling impairment. 
 
1.1.5 Hypocretin and respiratory control 
Because basal respiration and respiratory reflex regulations are different during 
wakefulness and sleep, HCRT may represent a link between vigilance state and 
vigilance state-dependent respiratory control (Nakamura 2007). 
The involvement of the lateral hypothalamus in both cognitive arousal and breathing 
was recognized many decades ago. In relation to breathing, a key prediction of a 
stimulatory role for the lateral hypothalamus was made by Redgate and Gellhorn in 
the 1950s. These authors used high-frequency currents to produce localized lesions in 
the lateral hypothalamus of lightly anaesthetized cats, while monitoring the rate and 
depth of respiration (Redgate 1958). The lesions resulted in an immediate decrease in 
the rate and/or depth of respiration, and these effects increased with the size and 
number of lateral hypothalamic lesions. Chemical inhibition of lateral hypothalamic 
activity, caused by injection of barbiturates, also reduced respiratory activity. On the 
basis of these data, Redgate and Gellhorn concluded that “impulses from the lateral 
hypothalamus exert a tonic facilitatory action on the respiratory centre”. This is 
supported by recent data revealing an anatomical ‘hotspot’ for breathing stimulation 
very close to the hypothalamic area where HCRT neurons are found. HCRT neurons 
project to different areas involved in respiration: the rostral vetrolateral medulla 
(RVLM), the pre-Bötzinger region (part of the respiratory rhythm generator), the 
NTS and the hypoglossal and phrenic nuclei (Williams 2008). 
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Central administration of HCRT-1 in mice increased the tidal volume (i.e. the amount 
of air inhaled or exhaled during normal ventilation). Effects were present shortly 
(within a few seconds) after the administration and lasted 10–40 min depending on 
the dosage. The responses were dose-dependent. However, the minimal dose 
producing a statistically significant response was 0.03 nmol for respiratory frequency 
and tidal volume and 0.3 nmol for blood pressure and heart rate, indicating that 
respiratory responses were not secondary to the cardiovascular changes (Zhang 
2005). 
Further evidence linking the HCRT system and breathing comes from mice with 
genetic deletion of the gene encoding prepro-HCRT.  
These mice showed an attenuated fight-or-flight response, including increases in 
respiration and BP, when exposed to stressors (Kayaba 2003), although basal 
ventilation was comparable to that in the control mice. This observation indicated that 
HCRT might be a master switch, which elicits integrated behavioral and autonomic 
outputs, modulating respiration only in a stress condition.  
In a series of recent papers, several clear abnormalities in the respiration of HCRT-
knockout mice were identified. When HCRT- knockout mice breathe normal room 
air, their respiratory frequency and tidal volume tend to be higher and lower, 
respectively, than those of control mice. Regardless the abnormal wake-sleep cycle of 
narcoleptic mice, minute ventilation results almost identical between strains during 
every behavioral state (Nakamura 2007). Therefore, HCRT does not appear to 
contribute to basal breathing when animals are at rest and under room air conditions. 
The situation changes when air composition is altered. The magnitude of the 
hypercapnic (5% CO2–21% O2 and 10% CO2–21% O2) and hypoxic (15% O2) 
ventilatory responses in both narcoleptic and control mice show a clear dependence 
on the behavioral state (Nakamura 2007).  
During wakefulness, increases in breathing caused by increased hypercapnia are 
reduced by 50% in the HCRT knockout mice (Nakamura 2007). On the other hand, 
no difference is found between HCRT-knockout and control mice in the hypoxic 
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ventilatory responses during W and in the hypercapnic ventilator responses during 
NREMS and REMS. 
These findings suggest that HCRT plays a crucial role both in CO2 sensitivity during 
wakefulness and in preserving ventilation stability during sleep. 
Considering that hypercapnic chemoreflex in prepro-HCRT knockout mice is 
attenuated during wake but not during the sleep period, Deng et al. administered an 
HCRT-1R antagonist (SB-334867) in wild-type controls before introducing a 
hypercapnic gas mixture in the plethysmographic chamber and showed that 
hypercapnic chemoreflex in those mice decreased without affecting their behavior. 
Supplementation of either HCRT-1 or 2 partially restored the hypercapnic 
chemoreflex in HCRT- knockout mice (Deng 2007). 
These results indicate that HCRT-1R is necessary for chemoreflex control. However, 
the response of HCRT-knockout mice to hypoxia is not different from that of wild-
type mice.  
Selective inhibition of both HCRT receptors by Almorexant, a dual HCRT receptor 
antagonist administered per os, induces an attenuated CO2 response by 26% only in 
wakefulness during the dark (active) period of the diurnal cycle, reaching the same 
level observed during NREMS in the light period in controls. Almorexant also 
decreases wakefulness and increases NREMS and REMS during the dark period, as 
previously reported, and unexpectedly decreases the number of sighs and post-sigh 
apneas during wakefulness in both the light and dark period and during both 
wakefulness and NREMS in the dark period (Kuwaki 2008). 
All these studies indicate that the HCRT system plays a critical role in central 
chemoreception during wakefulness, and the sleep–wake difference in the CO2 
response can be in large part attributed to HCRT. Hypocretins may also be involved 
in the mechanisms of stabilization of breathing. Post-hypoxic long-term facilitation, a 
physiological feature that is presumed to stabilize the respiratory control system and 
reduce sleep apnea, is absent in HCRT-knockout mice. The result is that HCRT-
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knockout mice also display a markedly increased frequency of spontaneous sleep 
apneas (Nakamura 2007).  
Narcoleptic patients also have a higher frequency of sleep apneas compared to 
healthy controls; this has been considered a disorder of respiratory control 
(Chokroverty 1986).  
There is evidence pointing to an impaired chemo-responsiveness in patients with 
narcolepsy-cataplexy. Sleep in narcoleptic patients is characterized by overwhelming 
excessive sleepiness occurring during the daytime and fragmented nocturnal sleep 
that is interrupted by numerous awakenings. A number of studies have demonstrated 
that one night of sleep deprivation significantly reduced both ventilatory chemo-
sensitivity and arousal responses in healthy adults (Schiffman 1983). The long-term 
nocturnal sleep disturbance in narcoleptics may alter the chemo-responsiveness and 
mimic the change of sleep deprivation. The fragmented sleep and hypoxia induced by 
a high incidence of sleep apnea may further impair the ventilatory responsiveness of 
these patients. 
Among sleep apneas, the most common in humans are the OSAs (Obstructive Sleep 
Apneas). These apneas are induced by the interruption of airflow in the upper 
airways, even if the respiratory muscles keep working. The apneic event causes a rise 
in BP and patients display a daytime hypertension and a higher cardiovascular risk 
(Davies 2000). In obese patients, the occurrence of OSAs is higher than in normal 
subjects. Narcoleptic patients are often obese, as a consequence of metabolic 
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A post-mortem study of narcolepsy patients found that hypocretin peptides were 
undetectable in the cortex and pons, in which HCRT projections are normally found, 
and that there was an 80-100% reduction in the number of neurons containing 
detectable prepro-HCRT in the hypothalamus (Thannickal 2000). This was supported 
by other reports that HCRT-1 was undetectable in the cerebrospinal fluid of 
narcolepsy patients (Nishino 2000).  
A recent finding showing concomitant loss of dynorphin, neuronal activity-regulated 
pentraxin and HCRT, which co-localize in HCRT- neurons, further indicates a loss of 
hypocretin neurons in narcolepsy-cataplexy (Crocker 2005). The cause of the specific 
loss or degradation of HCRT neurons in narcolepsy is unknown so far, but because of 
its strong association with specific human leukocyte antigen (HLA) alleles it has been 
hypothesized that narcolepsy results from selective immune-mediated degeneration 
of HCRT neurons, although no specific antibody against HCRT neurons has been 
found in the serum of affected subjects. 
 
2.1 Epidemiology 
Narcolepsy is a disabling sleep disorder characterized by excessive daytime 
sleepiness and abnormal REMS, manifestations including cataplexy (sudden loss of 
muscle tone triggered by strong emotions), sleep paralysis, and hypnagogic (sleep 
onset) hallucinations (Scammell 2003). Firstly described by Dr. Gelineau, narcolepsy 
is one of the most studied sleep disorders at a molecular level since it is a good model 
for studying REMS regulation and sleepiness in human beings, as well as the study of 
stimulant drugs. Studies performed in animal models showed that narcolepsy is 
produced by deficient HCRT transmission (Lin 1999). A striking decrease in HCRT-
1 concentrations in the cerebrospinal fluid (CSF) and in the number of HCRT 
neurons in post-mortem brain tissue have been reported in narcoleptic patients 
(Thannickal 2000). 
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In USA, the prevalence of narcolepsy with cataplexy is estimated between 0.05% and 
0.067%. The study of a cohort of 8000 twins from Finland, reported that 0.026% 
were affected by daily sleep attacks and at least one episode of muscular weakness 
per week. Similar data were also obtained from other studies performed in Europe, 
Hong Kong and MN, USA. The US study also reported an incidence of 0.74 per 
100,000 inhabitants per year. The prevalence of narcolepsy is higher in Japan and 
lower in Israel than in Europe and North America. Most studies found a slight male 
predominance. The age of onset is extended from early childhood to the 50s, with a 
bimodal distribution, including a large peak around 15 years of age and a smaller 
peak around 36 years. More than one half of narcoleptic patients report important 
events in the days or weeks preceding the onset of symptoms (excessive daytime 
sleepiness, cataplexy, SOREMPs). The gap between the emergence of initial 
symptoms and diagnosis is usually more than 10 years (Dauvilliers 2007).  
A tight association between narcolepsy and human leukocyte antigen markers HLA-
DR2 and HLA-DQB1* 0602 has been reported, but the roles of HLA (also called 
major histocompatibility complex or MHC) in narcolepsy are still not yet known. 
This HLA haplotype is relatively frequent in the general population, and only one out 
of 600 HLA-DR2 and HLA-DQB1*0602 positive subjects develops the disease. 
Because many HLA-associated diseases are known to be autoimmune, the discovery 
of an association between narcolepsy and HLA-DR2 led to the hypothesis that 
narcolepsy may result from an autoimmune process. Nevertheless, it is important to 
note that up to 10% of narcoleptic-cataplectic patients are HLA negative (Nishino 
2007). Therefore, environmental factors are also important for the development of the 
pathology, as substantiated by the fact that onset is not at birth but rather in 





- 36 - 
 
2.2 Clinical features 
ü Excessive daytime sleepiness: 
In most cases, daytime sleepiness is the first symptom to appear. It is also the most 
severe symptom and the most frequent cause for consultation (Scammell 2003). 
Daytime sleepiness occurs daily, recurring typically every 2 hours, although this can 
vary widely. Sleepiness is exacerbated when the patient is physically inactive. The 
sleep episodes have several characteristics: (1) they are often irresistible, despite the 
individual making desperate efforts to fight the urge to sleep; (2) they are usually 
short, although their length can vary with environmental factors (the duration can 
increase with passive activities such as watching television); (3) they are frequently 
associated with dreaming; and (4) they typically restore normal wakefulness for up to 
several hours. The refreshing value of short naps is of considerable diagnostic value, 
except in children who are frequently tired on awakening. Severe sleepiness can also 
lead to unconscious microsleep episodes or lapses (Dauvilliers 2007). 
ü Cataplexy 
Cataplexy is specific to narcolepsy and is the best diagnostic marker of the disease. It 
is characterized by a sudden drop of muscle tone triggered by emotional factors, most 
often by positive emotions such as laughter, repartee, pleasant surprise, or by anger, 
but almost never by stress, fear, or physical effort. All striated muscles (but not the 
diaphragm) can be affected, causing the individual to collapse. Cataplectic attacks are 
sometimes limited to facial muscles or to the arms or legs, with dysarthria, facial 
flickering, jaw tremor, head or jaw dropping, dropping of objects, or unlocking of the 
knees. The patient might not necessarily see these symptoms as pathological, given 
that they remain fully conscious during the episode. The duration of cataplexy varies 
from a split second to several minutes. Its frequency varies from less than one 
episode per year to several episodes per day. Cataplexy worsens with poor sleep and 
fatigue. Patients can occasionally have astatus cataplecticus”, which comprises 
continual cataplectic episodes lasting several hours. This state can occur 
- 37 - 
 
spontaneously but is more often seen on withdrawal from anticataplectic 
antidepressant drugs. Many neurophysiological and pharmaceutical studies indicate 
that cataplexy shares common neurophysiological mechanisms with REM sleep 
atonia (Dauvilliers 2007). 
Moreover, it has been shown that the dopaminergic system modulates cataplexy, 
sleep attacks and sleep-wake behavior in narcoleptic mice, with different mechanism. 
In particular, dopamine receptor modulation has powerful effects on sleep attacks and 
cataplexy. Activation and blockade of D1-like receptors has been shown to decrease 
and increase sleep attacks, respectively, without affecting cataplexy. Pharmacological 
activation of D2-like receptors increases cataplectic attacks and blockade of these 
receptors potently suppresses them (Burgess 2010). 
Specifically, brain imaging studies show that narcoleptics have an increased D2-like 
receptor binding that is tightly correlated with cataplexy. D2 receptors are also 
associated with the sleep attacks experienced by Parkinson's patients, who like 
narcoleptics, have hypocretin cell loss (Thannickal 2007).  
ü Other symptoms 
Narcolepsy includes sleep-related hallucinations and sleep paralysis. These symptoms 
are present in about 50% of those with the disease, but can also be seen in people 
who do not have narcolepsy. Hypnagogic or hypnopompic (on awakening) 
hallucinations can be auditory (the sound of a ringing phone, hearing someone 
walking on the stairs), visual (a threatening figure, passing shadows when driving, 
animals), or somesthetic (an out-of-body experience, where the person feels like 
someone is brushing against them). Even if patients are well aware retrospectively of 
the nature of these phenomena, some patients report difficulty in differentiating 
dreams from reality and  might occasionally be misdiagnosed as schizophrenic 
(Dauvilliers 2007). 
Sleep paralysis is an inability to move the limbs or the head or to speak or breathe 
normally either at sleep onset or on awakening (mainly from REMS) despite being 
mentally awake. It can be associated with hypnagogic hallucinations. Usually, sleep 
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paralysis does not last long (just a few seconds, but in rare instances can persist 
several minutes). 
Nocturnal sleep is disrupted in a third of patients. Typically, patients fall asleep as 
soon as they get into bed but wake up several times during the night.  
Narcoleptic patients also have higher body-mass indices than normal subjects. Some 
patients, especially children, gain weight after the onset of narcolepsy. 
Narcolepsy is also associated with increased Body Mass Indices (BMIs), increased 
prevalence of non insulin-dependent diabetes and sleep apnea syndrome. 
Periodic leg movements are also reported in narcoleptic patients, especially as they 
get older, but the contribution of these movements to daytime sleepiness remains 
controversial. Sleep-talking and REM sleep behavior disorders (in which patients 
physically enact their dreams) have been recorded in a third of patients. Depression 
has also been reported in 18-37% of cases. It is difficult to describe the general 
course of narcolepsy. In most patients, however, daytime sleepiness is the first 
symptom. Sleepiness and cataplexy persist throughout life although they often 
improve after retirement, probably due to better management of activities, daytime 
napping, and adjustment of nighttime sleep. By contrast, nocturnal sleep disturbances 
usually worsen with age (Dauvilliers 2007). 
 
2.3 Diagnosis 
The diagnosis of narcolepsy with cataplexy is based on excessive daytime sleepiness 
(occurring almost daily for at least 3 months) and on a history of cataplexy. The 
confirmation of clinical diagnosis can be carried out using with nighttime 
polysomnography, followed by a daytime multiple sleep latency test (MSLT).  
The aim of the polysomnography is to rule out other causes of daytime sleepiness 
(mainly sleep apnea) and to verify whether the patient slept enough (at least 6 h) 
before the MSLT. In 40% of cases polysomnography reveals a shortened REMS 
latency (less than 15 minutes), a fragmentation in REMS with imperfect loss of 
- 39 - 
 
muscle tone, an increased proportion of stage 1 sleep, and a relative augmentation in 
slow-wave sleep at the end of the night.  
The MSLT consists of five nap times, scheduled at 2-hourly intervals, starting at least 
1,5 h after awakening (Carskadon 1986). Each test is stopped after 15 minutes of 
sleep or after 20 minutes if the patient does not fall asleep. A sleep-onset REM period 
(SOREMP) is defined as the occurrence of REM sleep within 15 minutes of sleep 
onset. Since typical patients with narcolepsy frequently have two to five SOREMPs 
during MSLT, two or more SOREMPs are needed for the diagnosis. In narcoleptic 
patients the mean sleep-onset latency is usually shorter than 8 minutes, although 
latency increases with age. Polysomnography and MSLT must be performed in 
patients who are not under therapy, since drugs can substantially alter sleep-onset 
latency and the occurrence of REM sleep. 
Another diagnostic criteria commonly accepted by the American Academy of Sleep 
Medicine is the presence of the human leucocyte antigen HLA-DQB1*0602 genotype 
in patients, which is neither sensitive nor specific in narcolepsy, and can only 
support, not determine, diagnosis.  
Whenever possible, the diagnosis should be confirmed by measurement of HCRT-1 
levels in the cerebrospinal fluid (CSF), which must be less than or equal to 110 pg/ml 
or one third of mean control values in  order to qualify. HCRT-1 is measurable in the 
CSF and levels can be assessed by radioimmunoassay. Many authors assume that 
CSF HCRT-1 levels reflect the quantity of HCRT-1-producing cells in the 
hypothalamus. In a rodent study, a decrease of 50% in the CSF HCRT-1 levels was 
obtained after losing 70% of the HCRT-1-containing neurons (Gerashchencko 2003). 
Samples for the assessment of CSF HCRT-1 levels are obtained with a lumbar 
puncture during daytime. Some patients refuse this procedure, hindering a correct and 
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2.4 Experimental animal models of 
narcolepsy 
The first clues towards an involvement of hypocretins in narcolepsy came from 
animal models. Using forward and reverse genetics, two groups of researchers 
independently revealed the pathogenesis of narcolepsy. Either the lack of the 
hypothalamic neuropeptide HCRT (mouse gene knockout, KO; hypocretin-ataxin-3 
transgenic mice, TG), (Chemelli 1999; Hara 2001) or mutations in one of the HCRT 
receptor (HCRT-R) genes (autosomal recessive canine narcolepsy in Dobermans and 
Labradors), (Lin 1999) result in the narcolepsy phenotype. 
The first canine model of narcolepsy was identified in 1973. Narcoleptic dogs have 
cataplexy (mainly elicited by the presentation of food), sleepiness, and present 
SOREMPs. The disease is transmitted as a recessive autosomal trait with complete 
penetrance in Doberman Pinschers and Labrador Retrievers, whereas it is polygenic 
and determined by environmental factors (sporadic narcolepsy) in Poodles, Beagles, 
and other breeds. In 1999 a mutation in the gene coding for HCRT-2R was found as 
the cause of familial canine narcolepsy, resulting from decreased HCRT transmission 
(Lin 1999). This alteration consists in a single amino acid substitution (E54K) in the 
N-terminal region of the HCRT-2R. Results indicate a truncated HCRT-2R protein, 
an absence of proper membrane localization, and undetectable binding and signal 
transduction for exon-skipping mutated constructs (Lin 1999). 
Cataplexy in dogs closely resembles human cataplexy. Canine cataplexy is typically 
elicited during play with other dogs or with human caretakers; catching or retrieving 
objects, and tugging on towels or sticks are particularly effective triggers. Copulation 
will often elicit cataplexy in male narcoleptic dogs. Cataplexy can also be readily 
elicited by eating, particularly if the food is especially appreciated. In fact, 
narcoleptic dogs usually have about 2 episodes of cataplexy/hour during the day, but 
during the Food Elicited Cataplexy Test, they can have 5 or more than 5 episodes in 
just 1 or 2 minutes (Scammell 2009). 
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Well-characterized mouse models of narcolepsy with cataplexy have been produced 
with deletion of the prepro-HCRT gene and with transgenic expression of a toxic 
protein that selectively kills the HCRT-producing neurons. These mice have 
cataplexy-like behavioral arrests, poor maintenance of wakefulness, and fragmented 
sleep (Chemelli 1999), with occasional direct transitions to REMS from wakefulness. 
double knockout mice for HCRT-1R and HCRT-2R also exhibit similar phenotypes 
that have strong parallels with the human condition.  
HCRT knockout mice with congenital hypocretin deficiency were developed by 
Chemelli et al . in 1999. The researchers a targeting vector to replace exon-1 of pre-
pro HCRT gene by homologous recombination. The result was a null mutation in 
prepro-HCRT gene and an autosomal recessive narcoleptic phenotype. Mice carrying 
the mutation were then crossed with C57Bl/6J mice of the parental strain (this 
strategy is called “backcrossing”), in order to fix the mutation on a pure C57Bl/6J 
genetic background. Thus, mice were homozygous for the mutation and fully 
congenic to C57Bl/6J (Chemelli 1999). 
Hara et al. developed HCRT-ataxin-3 transgenic mice in 2001(ref. Chapter 5 for 
molecular details). 
 
Since narcoleptic patients do not have mutations in the prepro-HCRT or HCRT 
receptor genes, decreased HCRT levels in these patients is a consequence of a 
dysfunction or loss of HCRT-expressing neurons. This was confirmed by the 
discovery by Thannickal et al., who in 2000 described a global loss of HCRT neurons 
and residual gliosis in the brain of four narcoleptic patients.  
Thus, mice in which HCRT- containing neurons are specifically ablated would 
represent an useful model for human narcolepsy (Hara 2001). 
Brains of HCRT-ataxin-3 mice showed a progressive loss of HCRT-containing 
neurons as determined by anti-HCRT immunostaining. At postnatal day 5 no 
differences in the number of HCRT-containing neurons in HCRT-ataxin-3 mice and 
their wild-type littermates were detected. However 56% ± 12% of HCRT-containing 
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neurons were lost by 2 weeks of age. Thereafter, 75% ± 5% and 90% ± 8% of HCRT-
containing neurons were eliminated by 4 and 8 weeks of age, respectively. At 12 
weeks of age, more than 99% of HCRT-containing neurons were already lost and at 
15 weeks of age, nearly no HCRT-containing neurons could be found in the 
hypothalamic regions of all lines. These observations suggest that ablation of HCRT-
containing neurons occurs postnatally, and most drastically within 2 weeks after birth 
(Hara 2001). 
Phenotypically, prepro-HCRT knockout mice and HCRT-ataxin-3 transgenic mice 
are similar despite some differences. The first is that in prepro-HCRT knockout mice 
the congenital HCRT deficiency may lead to development of compensatory responses 
exerted by other neuronal circuits. 
Moreover, the loss of neuropeptides or neuromodulators co-expressed by HCRT- 
containing neurons may also contribute to phenotypic differences in these models. 
In the transition from active wake into cataplexy, the EEG changes from a typical 
waking pattern to one indistinguishable from REMS or the pre-REMS spindling often 
seen in mice. Once cataplexy is fully established, the EEG is dominated by high 
amplitude theta activity with an EEG power spectrum very similar to REMS. 
Bastianini et al. showed that short (1-2 s) high-amplitude bursts of pointed theta 
waves (7 Hz) occurred during either REMS or cataplexy in 80% of HCRT-deficient 
mice. Theta bursts were significantly more likely to occur during the dark period and 
in the last third of REMS episodes. Similar EEG events were detected in a 
significantly lower fraction (27%) of wild-type mice and with a significantly lower 
occurrence rate (0.8 vs. 5 per hour of REMS). These data demonstrate that 
occurrence of high amplitude theta bursts is facilitated during REMS and cataplexy in 
narcoleptic mice. The analysis of EEG frequency, and of daily and intra-episode 
patterns of event occurrence do not support the interpretation of theta bursts as 
temporally displaced pre-REMS spindles. Facilitation of high amplitude theta bursts 
may thus represent a novel neurophysiological abnormality associated with chronic 
HCRT deficiency (Bastianini 2011b). 
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Genetic factors and recording conditions may alter the frequency of cataplexy. 
Cataplexy occurs about four times more often in narcoleptic mice on a DBA/2J 
background compared to those on a C57BL/6J background (Hara 2005). 
The “International Working Group on Rodent Models of Narcolepsy” established a 
consensus definition of the features of murine cataplexy, expressing the confidence 
that it resembles human cataplexy closely enough for the term “murine cataplexy” to 
be appropriate. Murine cataplexy is defined as an abrupt episode of nuchal atonia 
lasting at least 10 seconds, during which the mouse is immobile. Theta activity 
dominates the EEG during the episode and at least 40 seconds of wakefulness 
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3.1 Influence of wake-sleep cycle on 
thermoregulation and cardiovascular 
autonomic control 
 
3.1.1 The wake-sleep cycle 
The wake-sleep cycle consists of the single sequence of at least three behavioral 
states, which are called wakefulness (W), non-rapid eye movement sleep (NREMS) 
and rapid-eye movement sleep (REMS). 
W is defined by a high electromyographic activity (EMG) and a desynchronized 
electroencephalographic activity with low-voltage rapid waves. 
NREMS or slow wave sleep, is easily distinguishable from both wakefulness and 
REMS by high voltage and synchronous EEG rhythms, including sleep spindles, K-
complexes and high-voltage slow waves, associated with low muscle tones and 
minimal physiological activity. In humans, NREMS is divided into four stages, 
corresponding with an increasing depth of sleep, as indicated by progressive 
dominance of the EEG by high-voltage, low frequency, “synchronized” wave activity 
(Rechtschaffen 1968). Such low-frequency waves dominate the deepest stages of 
NREMS (stages III and IV). The four NREMS stages (stages I, II, III, IV) roughly 
parallel a depth of sleep continuum, with arousal thresholds generally lowest in stage 
I and highest in stage IV sleep. NREMS is associated with fragmentary mental 
activity. REMS (or paradoxical sleep) requires the coincidence of specific activities 
in all three electrographic measures: “activated” or desynchronized EEG, bursts of 
rapid eye movements in the EOG and suppression of EMG activity. During REMS, 
the EEG pattern is characterized by a relatively low voltage, and mixed frequency 
(frequency in θ range is fairly common during REMS, particularly in proximity to 
eye movements). Activity in the α range (1-2 Hz slower than waking activity) may 
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also be seen in the REMS EEG. In REMS, muscles are atonic and dreaming is 
typical. Tonic and phasic events may occur during this state (Dement 2005). 
 
3.1.2Homeostasis and physiologic regulation during sleep 
The hypothalamus is a highly integrative part of the diencephalon, promoting specific 
behaviors by coordinating somatic, autonomic, and endocrine motor activity on the 
basis of external and internal sensory information (Zoccoli 2011). 
The role of the hypothalamus in this complex integrative activity is critical for the 
maintenance of body homeostasis. The principle of homeostasis in physiology was 
defined by W.B. Cannon in 1929 as “the coordinated physiologic processes which 
maintain most of the steady states in the organism” (Cannon 1929). The homeostasis 
can be experimentally tested across the behavioral continuum by studying the 
stimulus-response relationship in physiological functions at different levels of 
integration. The physiological homeostasis is maintained by effectors that minimize 
the influences of internal and external disturbances on the stability of fundamental 
variables such as temperature, pH, water volume, osmolality and nutrients. On the 
contrary, poikilostasis represents a condition in which an impairment of the stability 
of the variables is produced by effector activity (Parmeggiani 2005). Homeostasis is 
the result of continuous adjustments of “instrumental” variables such as HR, stroke 
volume, BP, cardiac output, vascular resistance and ventilation, which are directly 
affected by the activity of somatic and visceral effectors. 
Different physiological functions, such as thermoregulation, osmoregulation, 
regulation of energy balance and metabolism and autonomic cardiovascular control 
are closely linked to the regulation of wake-sleep cycle. Physiological variables 
change differently on passing from W to NREMS and from NREMS to REMS. These 
different behavioral states are characterized by either homeostasis (NREMS) or 
poikilostasis (REMS) of physiologic function. Physiological regulation is therefore 
organized at a hypothalamic level according to the different wake-sleep states. Thus, 
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wake-sleep states must be taken into account when physiological functions are 
studied (Parmeggiani 2005). 
An important difference between NREMS and REMS is that NREMS is functionally 
similar in different species, while REMS varies within and between species. NREMS 
is characterized by the assumption of a thermoregulatory posture and a decrease in 
muscle activity; from an autonomic point of view in this state there is the functional 
prevalence of parasympathetic influences over sympathetic activity. These 
peculiarities indicate a closed loop mode of operation that automatically maintains 
homeostasis at a lower level of energy expenditure compared with that found in 
wakefulness; the leading neural structures are diencephalic. Conversely, REMS is 
characterized by muscle atonia, rapid eye movements and myoclonic twitches; 
moreover, there is great variability in sympathetic activity and phasic changes in 
tonic parasympathetic discharge (Parmeggiani 2005). The variability of somatic and 
visceral phenomena of REMS is the result of open-loop operations of central origin, 
which impair the homeostasis; the leading neural structures are in this case 
rhomboencephalic (Parmeggiani 1980). 
This basic functional dichotomy may also be applied to the nervous control of  body 
temperature and of circulatory and respiratory functions.  
 
3.1.3Wake-sleep states and thermoregulatory control  
The hypothalamus represents the most important integrative center for the regulation 
of the body temperature. In mammals, homeothermy is controlled by preoptic 
hypothalamic integrative mechanism which drive subordinate brainstem and spinal 
somatic and visceral mechanism, thus eliciting thermoregulatory effector responses 
(Parmeggiani 2005). 
Thermoregulation and wake-sleep regulation strongly interact. During NREMS 
thermoregulatory mechanisms are operative, as they are in wakefulness, despite some 
state differences in the threshold and gain of effector responses to thermal loads and a 
down-regulation of body and hypothalamic temperatures, together with energy 
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expenditure.  The thermoregulatory responses to ambient thermal loads are present 
during NREMS and absent or depressed during REMS. During NREMS in cat, for 
example, its posture clearly varies in relation to the ambient temperature, while the 
drop in postural muscle tone during REMS is unrelated to ambient temperature 
(Parmeggiani 1970). Warm temperature notwithstanding, tachypnea in cats and heat-
exchange vasodilatation in cats, rabbits and rats disappear and sweating in humans 
decreases during REMS. In a similar way  with a cold temperature, shivering and 
piloerection in cats, and heat-exchange vasoconstriction in cats, rabbits and rats are 
suppressed during REMS. Moreover, the cold-defense function of brown fat is altered 
in rats (Parmeggiani 2005). Crucial proof of the behavioral state-dependent changes 
in the function of the preoptic-hypothalamic thermostat has been provided by 
experiments of direct thermal stimulation of preoptic-hypothalamic thermosensitive 
neurons across behavioral states in cats and rats. The change in thermosensitivity of 
the majority of such neurons parallels that found in thermoregulatory responsiveness 
to central thermal loads during NREMS and REMS. Indirect proof of this can be seen 
in the disappearance of shivering during REMS in a cold ambient in particular in cats 
with pontine lesions which produce REMS without muscle atonia (Parmeggiani 
2005). 
In conclusion, experimental evidence shows that during NREMS, thermoregulatory 
mechanisms are active as they are in wakefulness, despite some state-dependent 
differences in the threshold and gain of effector responses to thermal loads. The other 
difference compared to wakefulness is that, in NREMS, body and hypothalamic 
temperatures are regulated together with energy expenditure. 
Events in REMS are not only simply the result of state-dependent changes in 
threshold and gain of the different thermoregulatory responses; REMS is 
characterized by effector activity that is not only functionally inconsistent with the 
aim of temperature regulation but also lacks any proportional relationship with the 
intensity of the thermal stimulus. The conclusion is that the temperature of the body 
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changes according to its thermal inertia, as in a poikilothermic organism 
(Parmeggiani 2005). 
 
3.1.4 Wake-sleep states and cardiovascular regulation  
During a typical night’s sleep, autonomic patterns change dramatically, providing 
both respite and stress to the cardiovascular system. NREMS is associated with 
relative autonomic stability and functional coordination between respiration, the 
pumping action of the heart, and maintenance of arterial blood pressure. During 
REMS, surges in cardiac sympathetic and parasympathetic activity provoke 
accelerations and pauses in heart rhythm; these phasic alterations of  rhythm are a 
sign of a central nervous system activation (Verrier 2005). 
The cardiovascular changes in NREMS are consistent with changes in ventilation and  
thermoregulation in a condition of postural and motor quiescence (Parmeggiani 
2005). 
NREMS is characterized by a down-regulation of cardiovascular activity of variable 
intensity, depending on the species and on the previous level of cardiovascular 
activity in wakefulness (Parmeggiani 2005), with vagal nerve dominance and 
heightened baroreceptor gain (Verrier 2005). Recent studies on sleep onset in human 
subjects have shown that a progressive fall in BP ensues during relaxed wakefulness 
with the lights off (Carrington 2005). Conversely, in animal models, a decrease (in 
mice and dogs), (Schneider 1997; Schaub 1998) or no significant change (in cats, 
rabbits), (Mancia 1971; Cianci 1991) in BP has been reported on passing from 
wakefulness to NREMS (Silvani 2008). In humans, BP may decrease during NREMS 
due to a reduction in HR and, hence, in cardiac output, without significant changes in 
stroke volume or total peripheral conductance. A reduction in HR is, in fact, a 
common finding during NREMS in humans, as well as in experimental animal 
models, in which a reduction of BP is also detected (Silvani 2008). In cats, the 
reduction in HR during NREMS is attributed to an increase in vagal tone, because it 
is inhibited by vagotomy but not changed by ablation of the stellate ganglia (Baust 
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1969). However, in humans an early report showed a decrease in BP during NREMS 
without consistent changes in cardiac output (Bristow 1969). Moreover, a decrease in 
sympathetic nerve activity (SNA) directed to the skeletal muscle vessels has been 
shown in the deep stages of  NREMS compared to wakefulness during experiments 
on human subjects (Somers 1993). Finally, in rats, NREMS entails a decrease in renal 
SNA (Miki 2003) and an increase in renal vascular conductance (Yoshimoto 2004) 
compared to wakefulness in rats. These recent findings indicate that vascular 
conductance may increase during NREMS due to a decrease in sympathetic 
constrictor tone to the blood vessels in skeletal muscles and kidneys. The available 
evidence is too limited to determine the extent to which such an increase in 
conductance contributes to the reduction in BP during NREMS (Silvani 2008). 
Different phenomena characterize REMS in both humans and animals. Endogenous 
brain activation, typical of this state, is accompanied by a prominent variability of HR 
and BP (Verrier 2005). This variability is an important feature of REMS and it is 
generally associated with bursts of rapid eye movements, myoclonic twitches and 
breathing irregularities. 
During REMS in humans, mean BP increases compared to its values during NREMS. 
On the contrary, either a reduction or no substantial change in BP has been observed 
during REMS in different inbred mouse strains (Campen 2002). Early reports in cats 
showed a marked reduction in ABP during REMS, whereas an increase in BP has 
been reported during REMS of cats in more recent experiments, in which a longer 
postoperative recovery of the animals was allowed (Sei 1994). Thus, the reported 
changes in mean BP between NREMS and REMS are inconsistent both among and 
within species (Silvani 2008). Factors related to stress and thermoregulation may also 
be involved (Silvani 2008), and both prolonged postoperative recovery in cats and a 
shift of ambient temperature towards thermoneutrality in rats (Sei 1996) favour an 
increase in BP when passing from NREMS to REMS. It is worth noting that the 
impairment of thermoregulation during REMS also involves the hemodynamic 
adjustments driven by a thermal challenge in this state (Silvani 2008). During REMS, 
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an increase in mean BP was associated with an increase in HR in studies on humans 
(Khatri 1967). As far as HR changes during REMS are concerned, data obtained in 
rats are not consistent: an increase (Sei 1996), a decrease (Miki 2003) or no 
significant change (Zoccoli 2001) in HR have been reported during REMS. Similarly, 
in different inbred mouse strains, an increase, a decrease or no significant change in 
the mean value of HR has been observed during REMS without any apparent 
connection to changes in BP (Campen 2002). The changes in BP on passing from 
NREMS to REMS cannot be attributed to changes in cardiac output. The inconsistent 
relationship between changes in mean BP and those in HR and cardiac output suggest 
that differences in vascular conductance are involved in determining the 
hemodynamic pattern of REMS (Silvani 2008). Accordingly, in cats, early studies 
demonstrated an increased conductance of the splanchnic and renal vascular beds and 
a decreased renal SNA during REMS (Mancia 1971). An increased mesenteric 
vascular conductance (Miki 2004) and a decreased renal SNA (Miki 2003) have also 
recently been reported during REMS in rats.  
Taken together, these data indicate a substantial repatterning of sympathetic activity 
directed to the different vascular beds during REMS. However, these data do not 
clarify the extent to which the changes in vascular conductance contribute to the 
changes in BP on passing from NREMS to REMS (Silvani 2008).  
BP is controlled by two major nervous mechanisms, baroreflex and the central 
autonomic commands. They both act on the two branches of the autonomic nervous 
system (i.e. sympathetic and parasympathetic nervous system), eliciting different 
effects. The baroreflex operates a feedback control of BP in order to keep constant 
BP value in the face of perturbations. On the other hand, central autonomic 
commands may operate anticipatory feed-forward control of hemodynamics 
preparing the body for potentially dangerous situations such as the so-called fight-or-
flight response. This response thus involves changes in BP. The baroreflex and the 
central autonomic commands are likely to interact continuously but their actions and 
their relationship change according to body needs and behavioral states. 
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During NREMS, the contribution of the baroreceptor reflex in controlling heart 
rhythm has been demonstrated to be stronger than during either wakefulness or 
REMS. This distinctiveness of NREMS may in part underlie the greater stability in 
blood pressure observed during this state. The modification in the baroreceptor reflex 
mechanism in NREMS may be the result of a baroreflex change in sensitivity or a 
resetting compared to in wakefulness. The latter phenomenon is more consistently 
supported by experimental evidence in animal models and humans (Silvani 2008). 
Taken together, these findings suggest that the cardiovascular changes on passing 
from wakefulness to NREMS involve a resetting of the arterial baroreflex, but result 
primarily from centrally driven changes in the autonomic outflow to the heart and 
vessel resistance. To summarize, NREM sleep with its autonomic stability, provides a 
relatively salutary neurohumoral background during which the heart has an 
opportunity for metabolic restoration (Silvani 2008).  
During REMS central autonomic commands are thought to cause a repatterning of 
SNA directed to the different cardiovascular effectors (Silvani 2008). Central 
autonomic commands are also responsible for the phasic surges of BP described 
during REMS. The hemodynamic pattern of REMS is modulated by sinoaortic 
reflexes, but is not primarily caused by changes in their properties (Silvani 2008). 
Conversely, some evidence suggests a central origin of the hemodynamic pattern of 
REMS. In cats subjected to a mid-collicular transection, periods akin to REMS entail 
a decrease in BP and HR, which are associated with a decrease in the SNA directed to 
the heart and to the cutaneous, splanchnic and renal vascular beds and an increase in 
the SNA directed to the skeletal muscles (Futuro-Neto 1982). There is a striking 
correspondence between these findings and those often reported during physiological 
REMS in intact animals and humans, thus suggesting that, during REMS,  
stereotyped central autonomic commands produce a repatterning of the SNA directed 
to the different cardiovascular effectors. The variety of hemodynamic patterns and 
changes in BP that are observed on passing from NREMS to REMS are thought to 
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result, therefore, from a variable reflex modulation of this basic central command 
(Silvani 2008). 
There is growing evidence that nighttime BP values are prognostic for cardiovascular 
mortality. Ohkubo demonstrated that a diminished nocturnal decline in BP is 
predictable for cardiovascular risk and in particular, that each 5% decrease in the 
decline in the nocturnal BP was associated with a 20% increased risk for 
cardiovascular mortality (Ohkubo 2002). The physiological decline of BP on passing 
from wakefulness to sleep is usually defined as “non-dipping”. The mechanism of the 
action responsible for non-dipping is not clearly understood, but probably “non-
dippers” have an increase in sympathetic and a decrease in parasympathetic nervous 
system activity (Kohara 1996). The close relationship between wake-sleep 
architecture and dipping in BP has been shown in humans  (Loredo 2004) as well as 
in mice (Silvani 2009). 
 
3.2 Influence of ambient temperature on 
wake-sleep cycle and cardiovascular 
autonomic control 
 
3.2.1Central neural pathways involved in the regulation of 
body temperature 
Central neural circuits orchestrate a homeostatic repertoire for the maintenance of 
body temperature during environmental temperature challenges and for the alteration 
of body temperature during the inflammatory response. Morrison and Nakamura 
(Morrison 2011) recently summarized the functional organization of the neural 
pathways through which cutaneous thermal receptors control thermoregulatory 
effectors, i.e. cutaneous circulation for heat loss, brown adipose tissue, skeletal 
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muscle and the heart for thermogenesis, and species-dependent mechanisms 
(sweating, panting and saliva spreading) for evaporative heat loss.  
Briefly, when the hypothalamic temperature centers detect that the body temperature 
value is far from the set-point value, they institute appropriate temperature-decreasing 
or -increasing procedures. 
The temperature control system uses three mechanisms in order to reduce body 
temperature: 
• Vasodilatation of skin blood vessels, by inhibiting the sympathetic centers in 
the posterior hypothalamus that are responsible for vasoconstriction; 
• Sweating, which increases the rate of evaporative heat loss; 
• Decrease in heat production, through the inhibition of thermogenesis pathways. 
When body temperature is too cold, the temperature control system institutes exactly 
the opposite procedures (Guyton 2006). 
Thermogenesis, the production of heat energy, is an essential component of the 
homeostatic repertoire for the maintenance of body temperature during the challenge 
of low environmental temperature. (Morrison 2008). CNS thermoregulatory networks 
can stimulate thermogenesis in response to a cold environment, to a fall in core body 
temperature or to the presence of pyrogenic cytokines primarily in three tissues: 
brown adipose tissue (BAT), heart and skeletal muscle. 
Nonshivering thermogenesis in brown adipose tissue, shivering thermogenesis in 
skeletal muscles, thermoregulatory cardiac regulation, heat-loss regulation through 
cutaneous vasomotion and ACTH release (ACTH stimulates release of 
glucocorticoid, which then increases glucose availability and facilitates lipolysis to 
provide more fuel for thermogenesis) are involved in the regulation of body 
temperature. To defend thermal homeostasis from environmental thermal challenges, 
feed-forward thermosensory information on environmental temperature sensed by 
skin thermoreceptors ascends through the spinal cord and lateral parabrachial nucleus 
to the preoptic area (POA). The POA also receives feedback signals from local 
thermosensitive neurons, as well as pyrogenic signals of prostaglandin E2 produced 
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in response to infection. These afferent signals are integrated and affect the activity of 
GABAergic inhibitory projection neurons descending from the POA to the 
dorsomedial hypothalamus (DMH) or to the rostral medullary raphe region (rMR). 
Attenuation of the descending inhibition by cooling or pyrogenic signals leads to 
disinhibition of thermogenic neurons in the DMH and sympathetic and somatic 
premotor neurons in the rMR, which then drive spinal motor output mechanisms to 
elicit thermogenesis, tachycardia, and cutaneous vasoconstriction. Warming signals 
enhance the descending inhibition from the POA to inhibit the motor outputs, 
resulting in cutaneous vasodilation and inhibited thermogenesis. This central 
thermoregulatory mechanism also functions for metabolic regulation (Nakamura 
2011). 
During the rapid, repeated skeletal muscle contractions of shivering and during 
increases in heart rate, thermogenesis arises primarily from the inefficiency of energy 
utilization in cross-bridge cycling and calcium ion sequestration and, to a lesser 
degree, from mitochondrial membrane proton leaking in the course of ATP 
production from fuel substrate oxidation. The muscle contractions that characterize 
shivering result from rhythmic bursts of activity in the α-motoneurons, which 
innervate skeletal muscle fibres. The CNS network which generates the cold-evoked 
bursts of α-motoneuron activity is not well understood, but includes transmission of 
cutaneous cold afferent signals through the lateral parabrachial nucleus (LPB)  
(Nakamura 2008), integration of thermoregulatory signals in POA (Zhang 1995) and 
activation of fusimotor neurons that is dependent on neurons in the RVLM (Tanaka 
2001).  
The increases in heart rate in response to cold or during fever are sympathetically 
mediated and involve a neural network that parallels the one controlling the 
sympathetic activation of BAT thermogenesis (Morrison 2008). 
BAT is involved in non-shivering or adaptive thermogenesis. The specific metabolic 
function of this tissue is the heat-generating capacity induced by a significant 
facilitated proton leak across the extensive mitochondrial membranes of the brown 
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adipocytes, which occurs because of the high expression of uncoupling protein 1 
(UCP1) in BAT mitochondria. The level of BAT sympathetic nerve activity (SNA) 
and noradrenaline release and β3-adrenergic receptor binding to brown adipocytes 
determine the level of thermogenesis in BAT by regulating both the activity of lipases 
providing the immediate fuel molecules for BAT mitochondria and the level of 
expression of BAT mitochondrial UCP1. BAT has developed as an essential 
thermoregulatory effector in cold defense in rodents and other small mammals 
(Golozoubova et al. 2006), including infant humans. However, several recent 
observations, using positron emission tomographic scanning to assess tissue glucose 
uptake, have demonstrated a remarkable amount of BAT in adult humans, and the 
locations of BAT depots in adult humans bear a striking similarity to those in rodents: 
a large BAT pad in the vicinity of the scapulae and shoulders and individual pads 
atop each sympathetic ganglion and surround adrenal glands and kidneys. The 
curious localization of BAT pads, exemplified by those over each sympathetic 
ganglion, suggests that, in addition to the defense of core temperature in the cold, 
BAT may also serve to maintain optimal neuronal and synaptic function in specific 
locations in situations of reduced core body temperature. Similar to its function in 
smaller mammals, adult human BAT activity (assessed by glucose uptake) is highly 
responsive to β-adrenergic agonists and to environmental temperature (Morrison 
2008).  
Within the hierarchical organization of the central network controlling thermogenic 
thermoregulatory effectors, medullary neurons play key roles as premotor neurons, 
providing excitatory input to spinal motor neurons, for the circuits regulating 
sympathetic BAT thermogenesis, heart rate and somatic shivering thermogenesis 
(Morrison 2008). Physiologically, activation of neurons in the restricted region of the 
RVLM, including the rostral raphe pallidus nucleus (rRPa), whose activation leads to 
stimulation of cold-defense responses, increases BAT SNA, BAT thermogenesis and 
heart rate (Morrison 2008). Disinhibition of rRPa neurons following blockade of 
local GABA-A receptors with nanoinjections of  bicuculline elicits a large and 
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sustained increase in BAT SNA and BAT temperature and a sympathetically 
mediated tachycardia in anaesthetized rats with external body temperature support 
(Cao 2003) and a marked increase in heart rate with no change in body temperature in 
awake rats (Zaretsky 2003). These data indicate that when normothermic body 
temperature is maintained with an external heat source, the rRPa neurons controlling 
BAT SNA, the sympathetic outflow to the cardiac sino-atrial node and the discharge 
of motoneurons for skeletal muscle receive a tonic, GABAergic inhibition. In fact, 
inhibition of the activity in neurons in the rRPa reverses the increases in BAT SNA, 
BAT heat production and heart rate elicited by every thermogenic stimulus that has 
been tested (Morrison 2008). 
Thermoregulatory cardiac regulation is a very important component of the pathways 
facing ambient temperature changes. The cooling signals lead to disinhibition of 
thermogenic neurons in the DMH and sympathetic and somatic premotor neurons in 
the rMR, which then drive spinal motor output mechanisms to elicit thermogenesis, 
tachycardia, and cutaneous vasoconstriction. Warming signals enhance the 
descending inhibition from the POA, resulting in cutaneous vasodilation and 
inhibited thermogenesis (Nakamura 2011). The cooling-induced tachycardia is 
believed to facilitate the distribution of heat produced in thermogenic organs, as well 
as increase the availability of energy substrates to activated thermogenic organs. 
Furthermore, increased heart rate increases the amount of heat production in the heart 
(cardiac thermogenesis). But skin warming also increases heart rate. This warming-
induced tachycardia helps the heat-dissipating effect of the simultaneous cutaneous 
vasodilation by maintaining cardiac output and arterial pressure at a sufficient level to 
assure optimal increase in cutaneous blood flow (Nakamura 2011).  
Skin warming elicits cutaneous vasodilation, which is a heat defensive response: the  
increased skin blood flow facilitates the dissipation of body heat from the body 
surface. This response is mostly elicited through attenuation of cutaneous 
sympathetic nerve activity, whose tonicity regulates skin blood flow, even in a 
thermoneutral environment (Nakamura 2011). 
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3.2.3 Effect of ambient temperature on wake-sleep cycle 
Environmental temperature exerts complex effects on mammalian sleep and 
wakefulness (Parmeggiani 1970). In general, shifting the ambient temperature toward 
the thermoneutral zone increases the time spent in NREMS and REMS. 
Maintaining mice at a warm ambient temperature (30°C) increases time in both 
NREMS and REMS, whereas exposure to cold temperatures (10 or 18°C) reduces 
sleep (Roussel 1984).  
In order to assess the effects of ambient temperature on sleep, Jhaveri et al. evaluated 
the impact of three environmental temperatures (22, 26, and 30°C) on C57BL/6J 
mice under normal conditions, after sleep deprivation (SD), and during influenza 
infection (Jhaveri 2007). 
During the light phase, which corresponds to the rest period in nocturnal animals, the 
NREMS bout length was significantly longer in mice exposed to 30°C as compared 
to mice at 26°C, but the number of NREMS bouts did not differ significantly between 
the two Ta. 
Moreover, the time spent in REMS was significantly higher at 26°C as compared 
with mice housed at 22°C. These data indicate that a higher ambient temperatures 
promote spontaneous NREMS. Thus, laboratories in which sleep in mice is studied 
should expose animals to ambient temperatures ranging from 22 to 29°C. Data 
collected from mice housed under different temperatures may vary depending on an 
interaction between the ambient temperature and the condition of the animal. In some 
rodent species, even small fluctuations in ambient temperature can change the 
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3.2.4 Effect of ambient temperature on cardiovascular 
parameters and clinical implications 
Cardiovascular parameters such as BP and HR strongly depend on wake-sleep states 
but also on ambient temperature. Exposure of humans, rats, and mice to a cold 
ambient temperature results in elevated BP and HR. It appears as if the tachycardia 
and hypertension are the indirect result of sympathetic nervous system (SNS) 
activation of thermoregulatory mechanisms due to the fact that elevated plasma 
norepinephrine (NE) levels correlate with elevated blood pressure in the cold 
environment. Furthermore, propranolol, an adrenergic blocking agent, can blunt or 
completely reverse the cardiovascular effects of cold exposure. Cold-induced 
activation of the SNS, in turn, appears to elevate blood pressure through activation of 
the renin-angiotensin system (RAS). Genetic blockade of the RAS  genetically in an 
angiotensinogen-knockout mouse model blunts or prevents cold-induced 
hypertension (Sun 2003), suggesting that RAS signalling pathways are necessary for 
Ta-induced effects on BP. 
The elevation of Ta beyond typical housing temperatures also impacts on the 
cardiovascular system. Warming rats and mice from 23°C to 28-31°C, which is closer 
to, if not within, their thermoneutral zone (TNZ) results in a drop in heart rate and 
blood pressure. 
Swoap and colleagues demonstrated that the cardiovascular effects of changes in Ta 
are larger in mice than in rats; this is not surprising, considering that mice are 10 
times smaller than rats and therefore have a much greater rate of heat exchange 
relative to heat production than rats (Swoap 2004). 
Cardiovascular parameters and metabolic rate were measured in rats and mice over a 
series of Ta, ranging from 18° to 30°C. At any given Ta, BP, HR, oxygen 
consumption, and activity were elevated in the dark period compared to the light 
period, and  varied linearly with ambient housing temperature (Swoap 2004). 
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Under constant temperature conditions of 23°C, cardiovascular parameters and 
metabolic rate did not change in rats or mice over the same period of time (Swoap 
2004) and small incremental changes in Ta resulted in statistically different 
cardiovascular parameters. These findings demonstrated that, in the normotensive rat 
and mouse strains studied, there was a highly sensitive and linear effect of raising or 
lowering Ta within the range of 18-30°C on cardiovascular function.  
This cold-induced hypertension phenomenon appears to be dependent on 
thermoregulatory mechanisms, which operate via the SNS, as discussed above. Thus, 
there is strong evidence to suggesting that mammals increase SNS activity in 
response to thermogenic challenges (Swoap 2004). 
These data have an enormous impact from a clinical point of view. Many studies 
underline a linear association between ambient temperature and cardiovascular risk. 
The first study that estimated the impact of atmospheric variables on coronary heart 
disease morbidity in a population over a long period of time was published in 1999.   
Ambient temperature and pressure independently influenced myocardial infarction 
morbidity and mortality in the general population. A 10°C decrease in ambient 
temperature was associated with a 13% increase in total coronary event rates, an 11% 
increase in incident and coronary death rates, and a 26% increase in recurrent event 
rates (Danet 1999). 
A statistically significant increased risk of myocardial infarction at colder 
temperatures has recently been confirmed in other studies (Bhaskaran 2010).  
In this study, a broadly linear association between mean daily ambient temperature 
and risk of myocardial infarction was found, with a 1°C reduction in temperature 
associated with a cumulative 2% (95% confidence interval 1.1% to 2.9%) increase in 
risk of myocardial infarction over the current and subsequent 28 days (Bhaskaran 
2010). Several mechanisms have been proposed as explanations of the effect of 
temperature reduction on myocardial infarction risk. Exposure to cold under 
controlled conditions has been associated with an increase in arterial pressure, blood 
viscosity, and cardiac workload. A mobilization of granulocytes has been observed, 
- 62 - 
 
and red cell counts and plasma cholesterol and fibrinogen concentrations, all of which 
may be thrombogenic, seem to be raised after exposure to cold. Finally, one study has 
suggested that the density distribution of blood platelet subpopulations may be 
affected. These small experimental studies combine to suggest that a pathway for 
cold induced thrombogenesis might involve a combination of factors, including 
hemoconcentration, an inflammatory response, and a tendency for an increased state 
of hypercoagulability (Bhaskaran 2010). 
 
3.3 Interaction effect of Ta and wake-sleep 
state on cardiovascular parameters 
It is important to bear in mind that Ta and behavior may together influence 
cardiovascular parameters. Impairment of thermoregulatory peripheral vasomotion 
during REMS has been seen in experiments on rats, rabbits and cats exposed to 
various Ta (Parmeggiani 1977; Franzini 1982). In particular, during REMS, they 
observed that skin vessels were dilated at a low Ta while vasoconstriction increased 
paradoxically, at a higher Ta. 
The sympathetic nervous system, which controls skin blood vessels, was initially 
considered as playing an important role in thermoregulation, while sympathetic 
outflow to muscle blood vessels was involved in BP regulation. However, Fagius and 
Kay showed that, in humans, muscle sympathetic activity contributes to 
thermoregulation, and not only regarding the regulation of BP. Thus the elevation of 
BP and HR was considered to be related to heat production and to thermoregulatory 
vasomotion (Fagius 1991). Therefore, the thermoregulatory response to different Ta 
during sleep may include the change of muscle sympathetic nerve activity, thus 
affecting BP. However, Sei and Morita recorded the changes in mean arterial 
pressure (MAP) and HR during sleep at three Ta (16, 22 and 28C°) in rats. MAP and 
HR during sleep increased with the lowering of Ta. Indeed, the increase in MAP on 
passing from NREMS to REMS was diminished by lowering the Ta. At 28°C, HR 
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increased on passing from NREMS to REMS but decreased at 16°C (Sei 1996). This 
study suggested that Ta has a greater effect than sleep on cardiovascular parameters. 
These results highlight the idea that Ta and behavior have to be taken into account 
jointly when studying cardiovascular regulation; this is consistent with the findings 
that cardiovascular adaptations to ambient temperature changes are a part of neural 
pathways required for thermoregulation. This is particularly important in cases of 
hypocretin deficiency, given the pivotal role of the neuropeptide in thermoregulation, 
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The aim of this research was to investigate whether the effect of sleep and Ta on 
cardiovascular control depends on HCRT neurons. 
The hypothesis was that a lack of HCRT signaling is involved in the impairment of 
hypothalamic physiologic regulation, and in particular of cardiovascular 
thermoregulatory adaptations to different Ta.  To test this hypothesis, experiments 
were performed in a mouse model of HCRT deficiency, the HCRT-ataxin-3 
transgenic mouse. HCRT-containing fibers and HCRT receptors are present in 
several brainstem regions including the rostral raphe pallidus, a region of the 
ventromedial medulla which is a principal site of sympathetic and somatic premotor 
neurons regulating the activity of thermal effectors. These premotor neurons play an 
important role in the regulation of body temperature and in controlling BAT 
thermogenesis, energy expenditure and heart rate (Cao 2003). The increase in body 
temperature following ICV injection of HCRT is accompanied by an increase in 
sympathetic outflow (Yoshimichi 2001) as well as in heart rate, blood pressure, and 
renal sympathetic nerve activity (Shirasaka 1999). Thus, lack of HCRT signaling 
could result in reduced energy expenditure through decreased thermogenesis and 
physical activity, leading to obesity, despite the presence of hypophagia (Hara 2001). 
According to these data, core body temperature (Tb) in HCRT knockout mice with 
congenital HCRT deficiency was expected to be lower compared to controls 
(Mochizuki 2006). Surprisingly, Tb was the same in HCRT knockout mice and wild-
type littermates during sustained wakefulness, whereas it fell much less than normal 
during sleep in HCRT knockout mice. This blunted fall in Tb during sleep was 
probably due to an inadequate activation of heat loss mechanisms or to a sustained 
activity in heat-generating system in absence of HCRT signaling (Mochizuki 2006). 
Alterations in cardiovascular and thermoregulatory functions related to HCRT-
deficiency have also been found in human subjects. In fact, thermoregulatory 
cardiovascular control is impaired in narcoleptic patients (Fronczek 2006) and the 
related core body and skin temperature might causally affect vigilance and sleepiness 
in these patients (Fronczek 2008a). 
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Recently in this Lab it has been demonstrated that in HCRT-deficient mice, differ-
ences in BP between wakefulness and sleep states were blunted with respect to 
control mice; in particular, sleep-related physiological hypertension was significantly 
reduced, especially during REMS. These results provide proof of principle that 
chronic lack of HCRT signaling entails consequences regarding BP that are 
potentially adverse and that differ among wake-sleep states (Bastianini 2011a). Thus, 
the rationale of this research was to evaluate whether the blunted BP difference 
between wakefulness and sleep states in narcoleptic mice are modulated by Ta. This 
result, if positive, would be relevant for narcoleptic patients, given that a non-dipping 
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The study protocol was approved by the Bologna University ethics committee on 
animal experimentation and complied according with International Institutes of 
Health guide for the care and use of laboratory animals. 
5.1 Mice included in the experiment 
Hybrid transgenic mice with postnatal ablation of HCRT neurons (hTG) and wild-
type littermates (hWT) were included in these experiments. This strain was 
developed in the facilities of the Department of Human and General Physiology at the 
University of Bologna, with the purpose to obtain mice which were hemizygous for 
the HCRT-ataxin3 transgene with a mixed genetic background as in the original 
paper by Hara et al. (Hara 2005). 
We chose this mice model because it represents a useful model for human 
narcolepsy. It reproduces the patients’ phenotype well, with a global loss of HCRT 
containing neurons and residual gliosis in the perifornical region (Thannickal 2000), 
and presents smaller compensatory effects compared to congenital HCRT deficiency 
models.  
Transgenic mice with postnatal ablation of HCRT neurons (TG) were developed in 
2001 by Hara et al. (Hara 2001) by inserting a transgenic construct containing a toxin 
into mouse DNA. This transgenic construct is composed of the same human prepro-
HCRT gene fragment ligated to a cDNA fragment, which encodes from amino acid 
286 to the C terminus of elongated ataxin-3, isolated from a Machado Joseph Disease 
(MJD) patient. MJD is a rare autosomal dominant spinocerebellar type-3 ataxia in 
which neurons die because of the uncontrolled accumulation of the mutant form of 
ataxin-3 (Perez 1999). 
This abnormal form of the human ataxin-3 has an expanded polyglutamine stretch 
that induces cell apoptosis. From a patient with MJD, Hara et al. isolated the N-
terminally truncated portion of ataxin-3, which is sufficient to induce neuron 
apoptosis (Yoshizawa 2000) and put it next to the 5’-upstream region of the human 
prepro-HCRT gene. In these TG mice, which carry one copy of the transgene 
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containing the toxin (hemizygous mice), the hypothalamic HCRT-containing neurons 
gradually decrease in number, and are almost completely lost by 15 weeks of age. 
Previous experiments performed in the PRISM lab utilized TG mice backcrossed for 
13 generations and congenic to the C57Bl/6J strain (Bastianini 2011a). In the present 
study, in order to obtain hTG, male mice which were hemizygous for the HCRT-
ataxin3 transgene and congenic to C57Bl/6J (13 generations of backcrossing) were 
crossed with female (C57Bl/6J × DBA/2J) F1 hybrid mice (strain B6D2F1/J). 
hTG mice utilized in this experiment, similarly to mice studied by Hara et al. (2001) 
had 75% of their DNA which originated from the C57Bl/6J strain and 25% from 
DBA/2J strain. 
HCRT neuron-ablated mice with a mixed genetic background allow researchers to 
point out the metabolic abnormalities associated with human narcolepsy. The 
impairment of energy homeostasis in HCRT neuron-deficient transgenic mice 
(HCRT-ataxin-3 mice) is revealed by the development of late-onset obesity 
associated with a reduction in food intake. Beside the genetic background, 
environmental factors are also important in the development of obesity, stressing the 
role of genetic variability (Hara 2005). 
 
Experiments were performed on the following 2 age-matched groups of male mice: 
• 11 hTG mice, age at surgery 13.9 ± 0.5 weeks. 
• 12 hWT mice, age at surgery 15 ± 0.5 weeks. 
 
Mice were kept on a light-dark cycle of 12-hour periods with ambient temperature set 
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5.2 Experimental protocol 
PRISM lab has developed a combined, innovative, surgical technique which allows 
us to determine cardiovascular and sleep-wake phenotype simultaneously. 
In experimental animals, as in humans, techniques for measuring BP have improved 
considerably over the past decade. BP can be directly measured using radiotelemetry 
techniques, with the implantation of catheters connected to telemetric transducers. 
Implantable telemetry has the advantage of allowing for continuous, direct 
measurement of BP without the need for restraint in conscious freely-moving 
laboratory animals (Kurtz 2005). 
In this experiment, BP signal was obtained through a telemetric transmission device 
that is considered at the state of the art for the measurement of BP. 
One of the methodological limits of this technique is that it is impossible to record 
other biosignals along with BP. That is why EEG and EMG were obtained by the 
classical via-cable acquisition method, using the same technique used by group 
leaders in animal sleep research (Franken 1999). 
This combined technique allowed us to demonstrate that obesity may entail 
hypertensive derangements of BP, which are substantially modulated by the 
cardiovascular effects of the wake-sleep states (Silvani 2009), and to show that  the 
chronic lack of HCRT signaling entails consequences regarding BP that are 
potentially adverse and that vary widely among wake-sleep states (Bastianini 2011a). 
 
5.2.1 Surgical procedure 
Mice underwent surgery under general anesthesia (isoflurane, Abbott S.p.a., Pomezia 
Roma, Italy, 1-2%, NO2 70%, and balance O2) and sterile conditions, with the body 
temperature maintained at 37°C through a heating pad. 
The mice were subcutaneously injected with 200 µl of Rimadyl (Carprofen, Pfizer) 
diluted in saline solution 0.9%. 
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The mice were then implanted with a catheter inserted into the abdominal aorta and 
connected to a telemetric BP transducer (TA11PA-C10, DSI, Roermond, the 
Netherlands). The telemetric system also yielded a motor activity signal by 
quantifying the spatial shift of the transducer. All the surgical instruments were 
sterilized for 10 minutes at 134°C in an autoclave (Beta 35 Easy-lock, PBI, Milano, 
Italy). 
The right inguinal area of the mice was shaved and sterilized with iodine solution. 
One cm of the skin was cut and a subcutaneous pocket was created in the right flank 
of the animal. Using a Zeiss microscope at 16X magnifications, the femoral artery 
was carefully dissected from the nerve and the femoral vein, by removing the 
connective tissue. A 5-0 soft silk suture thread was permanently tied in the distal 
portion of the artery while a second suture thread was temporarily tied proximally to 
clamp the femoral artery, in order to arrest the blood flow. The catheter was then 
inserted in the distal portion of the artery, between the threads, through a hole made 
by a 90° bent needle (25 gauge). The tip of the catheter was placed between the iliac 
bifurcation and the renal arteries. The two silk suture threads were then tied in order 
to secure the catheter to the vessel. The telemetric transducer was inserted into the 
previously created flank pocket and fixed with surgical glue. Finally the skin incision 
was sutured with a 3-0 suture thread and covered with an antiseptic cream (Betadine 
solution 10%, Viatris, Milan, Italy). 
In the second half of the surgical procedure, the mouse head was fixed on a 
stereotaxic apparatus (51600 Lab Standard™ Stereotaxic Instrument, 2biol, Varese, 
Italy). The head was shaved and sterilized with iodine solution. The skin was cut on 
the midline from the frontal bone to the nuchal muscles. The periosteum was 
removed and the bone surface was cleaned. A pair of Teflon-coated stainless-steel 
electrodes (Cooner Wire, Chatsworth, CA, USA) were positioned in contact with the 
dura mater through burr holes to obtain a differential EEG signal.  The first wire was 
inserted 1 mm anterior and 1 mm right to Bregma in the frontal bone while the 
second wire was inserted 1 mm anterior and 1 mm right to Lambda in the parietal 
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bone. Another 3 holes were drilled on the left side of the skull in order to insert 3 
small stainless-steel anchor screws (2.4 mm length, Plastics One, Roanoke, VA, 
USA). 
A second pair of electrodes was inserted bilaterally in the nuchal muscles to obtain a 
differential EMG signal. All electrodes were connected to a miniature custom-built 
socket, which was then cemented to the skull with dental cement (Rely X ARC, 3M 
ESPE, Segrate, Milano, Italy), and dental acrylic (Respal NF, SPD, Mulazzano, 
Italy). At the end of the surgical procedure, an antibiotic solution (Benzilpenicillina 
Benzatinica, Biopharma) was administered subcutaneously. Then the mouse was left 
to recover for the rest of the day in a warmed cage at 30°C. 
 
5.2.2 Biosignal  recordings 
After a 17-day recovery period and habituation to the recording apparatus, BP and 
motor activity, and EEG and EMG signals were recorded simultaneously while 
keeping each mouse at a warm (30°C) and cold (20°C) ambient temperature, with 
exposure order balanced in each experimental group. In a sub-group of experimental 
animals (hTG, n=8 and hWT, n=9), biosignals were also recorded at 25°C, which was 
used as the baseline condition. The temperature of the recording box was modified 
the day before the beginning of biosignal recordings at each ambient temperature, in 
order to let mice adapt to the new conditions. 
Calibration of the telemetric BP transducers was performed using a high precision 
manometer (PCE P05, PCE Italy, Gragnano, Lucca, Italy), before implantation and 
after the end of the recordings. The TA11PA-C10 transducer was calibrated by 
inserting the catheter in a plastic chamber connected to a Riva-Rocci 
sphygmomanometer (PCE-P05, PCE Italy, Gragnano, Lucca, Italy). In the internal 
chamber different pressure values were set, from which it was possible to extrapolate 
a parabolic function then used to correct the BP signal. After this calibration, the 
TA11PA-C10 transducer was sterilized in a diluted solution (1:10) of peracetic acid 
(Nu Cidex®, Johnson & Johnson Medical, Rome, Italy). 
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The TA11PA-C10 transducer transmitted the BP signal by means of radio waves to a 
receiver (RPC-1, DSI) placed below the animal’s cage. The BP signal was then 
routed to a calibrated BP analog adapter (R11CPA, DSI) with compensation for 
barometric pressure (APR-1, DSI). The RPC-1 receiver also yielded an activity signal 
by quantifying the spatial shifts of the transducer due to mouse movements.  
The EEG and EMG signals were transmitted via cable. A rotating swivel 
(SL2+2C/SB, Plastics One) and a balanced suspensor arm prevented the cable from 
twisting and counterbalanced its weight, thus allowing the mice to make unhindered 
movements. The EEG and EMG signals were amplified and filtered (EEG: 0.3-100 
Hz; EMG: 100-1000 Hz; 7P511J amplifiers, Grass, West Warwick, RI, USA).  
All signals were digitized at 16-bit and 1024 Hz (PCI-6224 board, National 
Instruments, Austin, TX, USA). The EEG, EMG, and locomotion signals were down-
sampled at 128 Hz and stored together with the 1024 Hz BP signal. Data acquisition 
was performed by means of custom software written in Labview (National 
Instruments).  
   
5.2.3  Autopsy  
At the end of the experimental procedure, animals were euthanized under deep 
anesthesia (4% isoflurane). Brains were rapidly removed, checked for any 
pathological alterations produced by electrodes and screw implantation, and then 
frozen at -80°C in dry ice for HCRT quantification. The inguinal incision and the 
subcutaneous pocket were observed for any infection and the catheter was removed 
with care and calibrated again in order to verify its integrity. Two tail biopsies were 
taken to confirm the genotype. 
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5.3 Discrimination of wake-sleep states 
Data analysis was performed with custom software developed in Matlab and its 
Signal Processing Toolbox (The MathWorks Inc., Natick, MA, USA). 
A semi-automatic scoring of wake-sleep states was carried out on all consecutive 4-s 
epochs (Figure 1).  
A preliminary procedure was performed by identifying 3 clusters of epochs based on 
the root mean square (rms) of the EMG signal and the ratio between the EEG spectral 
power in the theta (6-9 Hz) and delta (0.5-4 Hz) frequency bands.  
Then all the epochs were displayed on a 3D graph in which the x-axis corresponded 
to the root mean square of EMG, the y-axis corresponded to θ/δ EEG power ratio, 
and the z-axis represented the density of epochs with those XY coordinates (Figure 
2). An algorithm set a cut-off region on the x-axis in correspondence of the minimal 
density between the two highest peaks. This cut-off automatically discriminated 
episodes of W (high EMG values) from those of sleep (low EMG values). A second 
cut-off region was fixed on the Y-axis between 0.75 and 1.25 based on preliminary 
data. All the epochs with higher values were automatically scored as REMS, whereas 
those with lower values were scored as NREMS. Episodes falling into the cut-off 
regions were marked as undetermined. 
After this automatic analysis, a wake-sleep state manual scoring was also performed. 
Visual scoring was based on the following criteria: W was scored when the EMG 
tone was high and the EEG was at low voltage with possible δ and θ frequency 
components. NREMS was scored when the EMG tone was lower than in W and the 
EEG was at high voltage with prominent δ frequency components. REMS was scored 
when the EMG indicated muscle atonia with occasional muscle twitches and the EEG 
was at low voltage with predominant θ frequency components. Automatic scoring 
thus helped to speed up the visual scoring. Manual scoring was performed by three 
trained researchers. 
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Analysis of sleep macrostructure was performed with a threshold of 12 s (i.e., three 
consecutive 4-s epochs) for each wake-sleep episode duration, and results were 
expressed relative to recording time which were free of EEG and EMG artifacts. 
Artifacts in EEG signal represented only 0.0417 ± 0.3% of the recording time spent at 
20°C and 0.0934 ± 0.6% spent at 30°C. 
Cataplexy-like episodes were scored following the consensus criteria established by 
Scammell et al. (Scammell 2009): 
• An abrupt episode of nuchal atonia lasting at least 12 seconds 
• Theta activity dominating the EEG during the episodes 
• At least 40 seconds of W preceding the episodes 
The last point is very important to distinguishing cataplexy-like episodes from REMS 
episodes. Cataplexy-like episodes were then excluded from all subsequent analyses. 
 
5.4 Analysis of cardiovascular variables 
Data analysis was performed using custom software developed in our laboratory in 
Matlab (The Mathworks, Inc). While performing the visual scoring of the wake-sleep 
states, investigators identified the 4-s epochs, in which artifacts do not allow for an 
accurate automatic determination of the beat-to-beat values of HR. These artifacts in 
the BP signal represented the following percentage of the total recording time: 5.9 ± 
2.4 % at 20°C and 9.6 ± 2.3 at 30°C. Cardiovascular analysis was performed on 2635 
hours of artifact-free recordings with Ta set at 20°C and 2533 hours of artifact-free 
recordings with Ta set at 30°C. 
Cardiovascular analysis was performed on 2635 hours of artifact-free recordings with 
Ta set at 20°C and 2533 hours of artifact-free recordings with Ta set at 30°C. 
Beat-to-beat values of mean BP and heart rate were computed from the raw BP signal 
(sampling frequency 1024 Hz) in each artifact-free 4-s epoch. Beat-to-beat values of 
mean BP (MBP) were computed by averaging all digitized raw BP values in each 
cardiac cycle. HR was computed in each 4-s epoch as the reciprocal of the average 
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time between the onset of successive systolic upstrokes. MBP and HR differences 
between exposure to 20°C and 30°C Ta (∆MBP20°C-30°C and ∆HR20°C-30°C) were then 
calculated within each behavioral state. Finally MBP differences between 
wakefulness and NREMS (∆MBPW-NREMS) and between wakefulness and REMS 
(∆MBPW-REMS) and between sleep states (∆MBPREMS-NREMS) were calculated for each 
Ta. 
To investigate the contributions of the baroreflex and central autonomic commands to 
cardiac control, we analyzed the cross-correlation function (CCF) between heart 
period (HP, i.e. the reciprocal of HR) and systolic blood pressure (SBP) values. The 
CCF yields the correlation coefficient between HP and SBP as a function of the time-
shift between these variables.  
A positive correlation between BP and HP fluctuations with negative time shifts 
reflects a prevalence of  baroreflex control of the heart whereas a negative correlation 
between these variables with positive time shifts indicates the prevalence of central 
autonomic commands (Silvani 2010). The CCF was computed for each mouse at each 
Ta.   
  
5.5 Statistical analysis 
Statistical analyses were performed using SPSS software (SPSS Inc., Chicago, IL, 
USA) with P<0.05 considered to be statistically significant. Data were analyzed by 
analysis of variance (ANOVA) and t-tests. Analyses involving within-subject factors 
were performed using the GLM procedure and the mixed-model design. 
Wake-sleep cycle data were analyzed using 2-way ANOVA with mouse strain (with 
2 levels: hTG and hWT) and Ta (with 2 levels: 20°C and 30°C) as factors. BP and 
HR data were analyzed with a 3-way ANOVA with mouse strain, wake-sleep state 
and Ta as factors. The wake-sleep state showed three levels: wakefulness, NREMS 
and REMS.  In the case of significant interaction effects, the simple effect of the 
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mouse strain was tested using t-tests with P<0.05 considered to be statistically 
significant.  
 
5.6 Measurement of brain HCRT-1 
In order to confirm complete genetic ablation of HCRT neurons in hTG mice, brain 
HCRT-1 was measured at the end of the experiments in hTG (n=4) and hWT (n=5) 
mice included in the cardiovascular analysis. 
The whole brain was removed immediately after decapitation under deep 
isoflurane/N2O anesthesia, and frozen at -80°C for subsequent processing. The brains 
were grossly dissected in 8 blocks, boiled for 10 minutes in 2.5 ml acetic acid 0.5 
mol/l, and flash-cooled on ice. One aliquot (50 µl) of the supernatant was taken for 
measurement of total protein concentration in duplicate with the Lowry technique 
(DC protein assay, Bio-Rad Italy, Segrate, Italy, with bovine serum albumin as 
standard). Two 50 µl aliquots were dried overnight in siliconized (Sigmacote, Sigma-
Aldrich Italy, Milano, Italy) cryotubes under a fume cupboard hood for HCRT-1 
measurement. HCRT-1 measurement was performed in triplicate with a fluorescent 
immunoassay kit (FEK 003-30, Phoenix Pharm. Inc., Burlingame, CA, USA; range 
0-10,000 pg HCRT1/ml) after reconstituting the dried peptide solutions in 125 µl 
assay buffer, following the manufacturer’s instructions. All samples were processed 
simultaneously on the same immunoassay plate with a manufacturer-determined 
detection threshold of 20.3 pg HCRT-1/ml.  
 
5.7 Quantitative Real Time PCR 
An ancillary experiment was performed on 3 young mice (2 hTG and 1 hWT, aged 8 
weeks) to test the expression of prepro-HCRT, Ataxin-3 and GAPDH genes 
quantifying their brain mRNA levels. The golden standard technique for the 
evaluation of RNA expression is the conversion of  RNA into complementary DNA 
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(cDNA) followed by a Quantitative Real Time PCR (qRT-PCR). Briefly this 
procedure is based on the extraction of RNA from tissues of interest, its conversion 
into cDNA by reverse transcription and then quantification of genes of interest 
evaluating their amplification in a qRT-PCR with a DNA-intercalating fluorescent 
dye. For this experiment, genes of interests (i.e. prepro-HCRT and Ataxin-3) were 
normalized to the expression of GAPDH (housekeeping gene). Results were analyzed 
with a free trial version of qBase Plus and presented as relative expression to 







































- 82 - 
 
6.1 Validation of  mouse model of narcolepsy 
In order to assess the lack of  HCRT signaling in the mice used in the experiments, 
we used three complementary approaches. Firstly, we verified the presence of the 
transgene using a polymerase chain reaction (Figure 3), (ref. Appendix for more 
detailed informations). The second approach was based on proteins measurement: we 
dosed brain HCRT-1 with a fluorescent immunoassay kit. In all hTG mice HCRT-1 
brain levels were below the detection threshold, whereas they were over this 
threshold in hWT. In hTG, brain HCRT-1 concentration was 4.0 ± 0.2 fmol/mg total 
protein, whereas it was 51.0 ± 0.6 fmol/mg total protein in hWT mice (Figure 4). The 
third approach was based on the quantification of brain mRNA levels of prepro-
HCRT and Ataxin-3, using a qRT-PCR technique. Data shown in Figure 5 confirmed 
that the hTG mice had drastically reduced prepro-HCRT expression levels and, 
moreover, they produced Ataxin-3, whereas hWT mice showed a higher expression 
of prepro-HCRT and a complete absence of Ataxin-3 expression.  
 
6.2 Wake-sleep behavior at different Ta 
The wake-sleep cycle structure changed as a function of Ta with no statistical 
difference between strains (Table 1), except for REMS latency. On passing from 
20°C to 30°C the amount of time spent in wakefulness significantly decreased while 
the percentage of time spent in REMS significantly increased. Time spent in NREMS 
also tended to increase at 30°C (P = 0.089) (Table 1). 
The density of  W (i.e. number of episodes occurring in 24h) was higher in hTG mice 
both at 20°C and 30°C. The density of NREMS episodes was higher in hWT at 30°C. 
No statistically significant difference was found regarding the density of REMS 
episodes at either Ta (Table 2). 
The duration of W episodes (sec.) was lower in hTG mice at both ambient 
temperature, in accordance with the difficulty of consolidating W that is presented in 
narcoleptic patients. NREMS episodes lasted longer at 30°C than at 20°C . The 
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duration of REMS episodes was lower at 20°C with no difference between mouse 
strains (Table 2). 
Locomotor activity was not affected by Ta but depended on the mouse strain and it 
was higher in hWT mice at both 20°C and 30°C (data not shown). 
To summarize, independently of Ta, hTG mice conserved their narcoleptic 
phenotype, showing a fragmentation of waking behavior (i.e. lower bout duration and 
higher number of episodes) and a significant reduction in REMS latency compared to 
hWT mice. Nevertheless the reduced REMS latency observed in hTG mice was 
significantly lower at 20°C. 
The narcoleptic phenotype was also confirmed in hTG mice by the occurrence of 
SOREM periods (SOREMPs). hTG mice showed 4.9 ± 1.9 SOREMPs during total 
recording time with Ta set at 20°C, and 5.8 ± 3.8 with Ta set at 30°C. This difference 
was not statistically significant. No SOREMPs were found in hWT mice. 
 
6.3 Effect of Ta on MBP and HR 
Figure 6 and 7 illustrate the effect of Ta on cardiovascular variables during each 
behavioral state for both hTG and hWT mice. Measurements were performed at 
20°C, 25°C, and 30°C. To simplify, the results of the 3-way ANOVA are reported in 
Table 3. 
The ANOVA highlighted significant effects of the wake-sleep state and Ta on MBP 
and HR values (P < 0.001) whereas it failed to show any statistical differences 
between mouse strains (P > 0.1). In both hTG and hWT mice MBP and HR were 
significantly higher at 20°C, decreasing when passing from 20°C to 25°C and 
decreasing even further when the temperature rose to 30°C in all wake-sleep states 
(Figures 6 and 7). 
The ANOVA also showed evidence of a significant interaction effect between wake-
sleep state and Ta on cardiovascular variables: both the difference in MBP 
(∆MBP20°C-30°C) and in HR (∆HR20°C-30°C) between 20°C and 30°C exposure, 
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significantly changed as a function of wake-sleep state (Figure 8) and were highest in 
NREMS. This effect of Ta on MBP was significantly lower in REMS than in either 
NREMS or in wakefulness regardless of the mouse strain. 
Finally, the ANOVA showed an interaction effect between wake-sleep state and 
mouse strain on MBP and HR values. The data shown in Figure 9 confirms that the 
physiological sleep-related decrease of MBP was blunted in hTG mice independently 
of Ta variations: ∆MBPW-NREMS  and ∆MBPW-REMS  were significantly smaller in hTG 
than in hWT, whether at 20°C or 30°C (Fig 9). At 30°C MBP differences between 
sleep states were enhanced. 
Table 4 shows that ∆MBPREMS-NREMS  was much higher when all mice were kept at 
30°C than when they were kept at 20°C.  Interestingly, the magnitude of the 
∆MBPREMS-NREMS  increase was exactly the same for hTG and hWT mice. The same 
pattern was the same for HR values (data not shown). 
To summarize, MBP was higher in wakefulness than in either NREMS or REMS. 
This effect of sleep on blood pressure was significantly reduced in mice lacking 
HCRT neurons at each Ta, both in the dark and light periods, and particularly during 
REMS, confirming recently published data (Bastianini 2011a). 
 
6.4 Cross correlation function (CCF) 
analysis 
The average CCF profiles for both hTG and hWT mice kept at 20°C and 30°C are 
shown in figure 10. The maximum and minimum values of the CCF during each 
behavioral state at 20°C (red and blue lines) and 30°C (green and black lines) were 
similar between hTG and hWT. On the other hand, Ta showed an important effect on 
the CCF profiles of both strains in each behavioral state. This was particularly 
evident during REMS (Figure 10, bottom panel). Heart rhythm was mainly 
modulated by baroreflex control (cf. a prominent positive peak at negative time shift) 
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at 20°C, whereas central autonomic commands prevailed (cf. a deep throat at positive 
time shift) at 30°C. 
To be more specific, during wakefulness at 20°C baroreflex and central commands 
equally contributed to heart rate control in both hTG and hWT mice. At 30°C central 
command contribution increased significantly in both strains. 
During NREMS, baroreflex prevailed on HR control regardless of Ta. At 30°C 
central command contribution increased in both strains. 
During REMS, in both strains, baroreflex control of HR prevailed at 20°C whereas 
central command control prevailed at 30°C. 
Considering that no statistically significant effect of mouse strain was found, the 
balance between baroreflex and cental autonomic control of the heart is not 
dependent on HCRT neuron activity but changes as a function of wake-sleep states 
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7.1 Genetic ablation of HCRT neurons blunts 
the effects of sleep but not those of Ta on blood 
pressure in mice 
The main finding of this research support the hypothesis that HCRT neurons are part 
of central neural pathways that mediate the phenomenon of BP dipping on passing 
from wakefulness to sleep, whereas they do not play a critical role in mediating the 
cardiovascular responses to different Ta. 
 
Ta exerts a prominent influence on sleep. In rats and humans, low ambient 
temperatures generally impair sleep, whereas higher temperatures tend to promote 
sleep (Jhaveri 2007). Thermoregulation changes according to behavioral states. The 
thermoregulatory responses to ambient thermal loads are preserved during NREMS 
and are absent or depressed during REMS (Parmeggiani 2005). Furthermore, Ta and 
wake-sleep behaviour may together affect cardiovascular parameters (Sei 1994). 
Cardiovascular parameters such as BP and HR, strictly depend on Ta, especially in 
small animals like rodents in which the great surface area-to-volume ratio makes 
them more sensitive to Ta changes (Swoap 2004). Moreover, research performed in 
the PRISM lab has recently demonstrated that wake-sleep behavior deeply affects BP 
and HR values in different genetically-modified mouse strains (Silvani 2009; 
Bastianini 2011a). 
Consistent data indicate a strong anatomical and functional integration between 
hypothalamic regulatory mechanisms of energy homeostasis, autonomic 
cardiovascular control, thermoregulation and wake-sleep states. HCRT is a good 
candidate for playing a pivotal role in the coordination of these entangled 
mechanisms.  
We performed experiments on a group of narcoleptic mice with selective loss of 
HCRT neurons (hTG) and their wild-type littermates (hWT). In order to investigate 
the role of HCRT neurons in cardiovascular responses to different Ta, we 
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characterized the cardiovascular phenotype of the mice during the wake-sleep states 
at warm and cold Ta. 
As expected, hTG mice showed a narcoleptic phenotype, with a fragmentation of 
waking behavior (i.e. lower bout duration and higher number of episodes) and a 
significant reduction or REMS latency compared to hWT mice. 
Moreover, our results confirmed the influence of Ta on the wake-sleep cycle 
macrostructure; we found an increase in sleep for both hTG and hWT when thet were 
exposed to warm Ta. Numerous studies have suggested the involvement of HCRT 
neurons in the regulation of body temperature. Cardiovascular changes participate in 
mechanisms that mediate thermoregulation (Morrison 2011). Thus, we tested the 
hypothesis that the chronic lack of HCRT signaling may lead to abnormal 
cardiovascular responses to Ta changes.  
In both humans and animals, the main thermoregulatory effectors include cutaneous 
blood vessels for control of heat loss, brown adipose tissue, skeletal muscle and 
increased HR for thermogenesis (Morrison 2011). The presence of cardiovascular 
adaptations to thermal loads is well known due to studies on small rodents. Exposure 
of rats and mice to cold Ta produces cutaneous vasoconstriction (ears and tail) and 
non-shivering thermogenesis in brown adipose tissue, which is activated by the 
sympathetic nervous system through the release of catecholamines (Swoap 2004). 
The activation of the sympathetic nervous system in response to a cold environment 
also has direct effects on the heart, increasing cardiac thermogenesis (Morrison 
2011). As a consequence of this general sympathetic activation, exposure to cold Ta 
determines increases in BP and HR values possibly leading to hemodynamic 
derangements and increased myocardial risk, as also demonstrated on human subjects 
(Danet 1999).  
The link between HCRT and thermoregulation has been deeply investigated. ICV 
injection of HCRT-1 evoked hyperthermia (Monda 2003). Neurons in the lateral 
hypothalamic area, where HCRT neurons are localized may influence brown adipose 
tissue sympathetic nerve activity, thermogenesis and HR through the activation of 
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neurons in the dorsomedial hypothalamus and raphe pallidus (Cerri 2005). This last 
result has been recently confirmed by Tupone et al., who have suggested a potent 
modulation of brown adipose tissue thermogenesis by HCRT released from the 
terminals of HCRT neurons into the raphe pallidus (Tupone 2011). The involvement 
of HCRT neurons in thermoregulation is also confirmed by the response of muscimol 
(GABA-A receptor agonist) injection in the preoptic hypothalamic area. The 
muscimol perfusion in POA induces c-Fos expression in HCRT neurons suggesting 
that subpopulations of the preoptic neurons give an inhibitory tone to the activities of 
the HCRT neurons in the perifornical/lateral hypothalamic areas and that removing 
this tone contributes to an increase in body temperature, HR and BP (Satoh 2004). 
Consistently with these results, a chronic lack of HCRT would be expected to disrupt 
those responses required for thermoregulation. Results obtained in animal models of 
narcolepsy are contrasting, showing an increase in core body temperature during 
sleep in HCRT knockout mice (Mochizuki 2006) or a diurnal rhythm of core body 
temperature in HCRT-ataxin-3 transgenic mice similar to that recorded in their WT 
littermates (Zhang 2007). 
Studies in narcoleptic patients reported no defects in thermoregulation suggesting a 
marginal role of HCRT in this regulation (Grimaldi 2010a). On the other hand, some 
studies found instead that thermoregulatory cardiovascular control is impaired in 
narcoleptic patients (Fronczek 2006); it has been suggested that the related core body 
and skin temperature alterations might causally affect vigilance and sleepiness in 
these patients (Fronczek 2008a).  
 
The rationale of the present study was that HCRT deficiency in HCRT-ataxin-3 
transgenic mice would suppress the general sympathetic activation induced by 
HCRT, leading to impairments in thermoregulatory responses to thermal loads and in 
particular in cardiovascular responses to Ta changes. Nevertheless, no significant 
difference in the cardiovascular responses to the different Ta was found, suggesting 
that HCRT neurons are not necessary for cardiovascular adaptations to different Ta. 
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Additional experiments, aimed at measuring core body temperature, could reveal 
other disturbances in thermoregulatory function as a consequence of HCRT 
deficiency. 
hTG mice and hWT mice showed the same cardiovascular responses to Ta changes. 
Both MBP and HR increased in a cold environment and decreased gradually on 
passing from 20°C to a warm environment (30°C).   
Thermoregulatory and cardiovascular responses are strictly dependent on wake-sleep 
states. Changes in blood flow during NREMS reflect thermoregulatory vasomotor 
adjustment and depend on Ta. In contrast, REMS appears to be a state in which 
changes in regional blood flow indicate a disruption in thermal homeostasis. This 
assumption is confirmed by the obtained results: cardiovascular adaptation to Ta 
changes (∆MBP20°C-30°C and ∆HR20°C-30°C) is highest during NREMS in both mouse 
strains. Accordingly, NREMS is characterized by relative autonomic stability, with 
vagal nerve dominance and reduced sympathetic nerve activity (Somers 1993), and 
shows an enhanced homeostatic control compared to wakefulness. On the other hand, 
both ∆MBP20°C-30°C and ∆HR20°C-30°C significantly decreased on passing from NREMS 
to REMS, in agreement with the depressed thermoregulation associated with the 
latter behavioral state (Parmeggiani 2005). Sei and Morita (Sei 1996) demonstrated 
that in rats BP difference on passing from NREMS to REMS decreases at low Ta. 
Our data confirmed these observations in mice. This response was the same in hTG 
mice and in hWT mice, thus sustaining the hypothesis that HCRT neurons are not 
implicated in this phenomenon. 
HCRT neurons participate in the maintenance of energy homeostasis (Funato 2009) 
on different time scales. In the long term, in the absence of HCRT, mismatches 
between metabolic rate and caloric intake may lead to the increased body weight that 
often characterizes narcoleptic patients. On the other hand, the short-term balance 
between production and energy dissipation is a function of temperature regulation, 
and, as a consequence any imbalance should imply a change in body temperature. 
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Narcolepsy is often associated with an increase in body weight/body mass index 
(BMI); weight gain usually seems to be independent of caloric intake, which is 
paradoxically lower in narcolepsy patients (Lammers 1996). On the basis of an 
increased heart rate variability, a reduced sympathetic tone has been proposed in 
narcoleptic patients (Fronczek 2008b ). The autonomic system innervates white and 
brown (BAT) adipose tissue, inducing catabolic processes through sympathetic 
inputs, and anabolic processes, through parasympathetic inputs, Thus, a sympathetic 
tone reduction could explain the increased fat accumulation observed in narcolepsy. 
The mouse strain that we used in these experiments is particularly suitable for 
evaluating the presence of an imbalance in the short-term energy homeostasis 
maintenance. In fact, HCRT-ataxin-3 transgenic mice with a mixed C57BL/6J plus 
DBA/2J (3:1) background display a marked late-onset obesity compared to their 
controls (Hara 2005), despite eating less; they are also more sensitive to the 
development of metabolic alterations than narcoleptic mice with a pure genetic 
background. This predisposition to the development of obesity is not yet fully 
expressed in young adult subjects, and accordingly, the weight of the studied animals 
did not differ significantly between mouse strains, hTG mice weighing 29.2 ± 0.7 g 
and in hWT mice weighing 28.6 ± 0.8 g. 
Finally, using the CCF analysis between spontaneous fluctuation of systolic BP and 
heart period, the relative contribution of baroreflex and central autonomic commands 
on heart control was assessed. The interplay between these two control mechanisms 
was deeply affected by the wake-sleep cycle in both mouse strains, confirming 
previous observations (Silvani 2010). In mice, as in rats and humans, the contribution 
of central autonomic command is prevalent during REMS, particularly at 30°C. No 
evident difference was found between hTG and hWT mice either in the maximum or 
minimum values of CCFs. In REMS, during the exposition to 20°C, the related 
contribution of central autonomic commands to cardiac control is less evident in both 
mouse strains and this is probably due to the elevated basal values of HR, induced by 
lower 
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7.2 Conclusion 
In conclusion, this study demonstrated that in mice cardiovascular adaptations to Ta 
changes strongly depend on the wake-sleep states whereas HCRT neurons do not 
seem to be involved in this process.  
These results confirm the recent finding that HCRT-deficient narcoleptic mice have 
blunted BP differences between wakefulness and sleep states (Bastianini 2011a). 
Moreover, BP derangements induced by HCRT deficiency seem to be highly 
reproducible regardless of Ta changes. 
A marked hypertension in HCRT-deficient mice has never been found before. Rather, 
a marked hypotension was reported both in HCRT knockout mice and HCRT-ataxin-
3 transgenic mice compared to control mice (Kayaba 2003; Zhang 2006). These 
discrepancies could be attributed to methodological differences but also to the fact 
that in previous studies sleep-dependent cardiovascular modifications were 
disregarded. Moreover, a marked hypotension has never been reported in narcoleptic 
patients, who suffer from a selective loss of HCRT neurons. Rather, narcoleptic 
patients were hypertensive compared to patients with idiopathic hypersomnia (Baker 
1986) or  there was no difference in BP measurements throughout the night compared 
to normal control subjects (Guilleminault 1986). 
To conclude, the genetic ablation of HCRT neurons blunts only the effect of sleep but 
not those of Ta on BP in mice, leading to a neurogenic hypertension during sleep and 
in particular during REMS. The possible explanation of this result is that, although 
HCRT neurons almost stop firing in NREMS and REMS, brain interstitial HCRT 
remains substantial during sleep in the interstitial fluid (i.e. volume transmission). 
Thus when synaptic activity of HCRT neurons is almost nil, as in NREMS and 
REMS, the residual volume transmission exerted by interstitial HCRT may entail a 
vasodepressive tone, in the absence of which BP increases. The second hypothesis is 
that the lack of HCRT signaling entails compensatory mechanisms during W that also 
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continue to act during sleep, thus compensating for the loss of HCRT effects during 
wakefulness. 
HCRT neurons seem to be involved in a neural pathway that mediates the 
phenomenon of blood pressure dipping on passing from wakefulness to sleep.  
Several studies have revealed an association between non-dipping BP profile and 
increased cardiovascular risk (Ohkubo 2002). This concept may have clinical 
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There is evidence that hypocretinergic neurotransmission interacts with many other 
hypothalamic regulatory systems to mediate different physiological functions. 
In particular, the relationship between hypocretinergic function and histaminergic 
function seems to be involved in the regulation of the wake-sleep cycle and 
cardiovascular regulation. 
HCRT neurons project downstream to the tuberomamillary nucleus (TMN) in the 
posterior hypothalamus, where histaminergic neurons are localized. The 
histaminergic system is exclusively localized within the posterior hypothalamus with 
projection to almost all the major regions of the central nervous system. Strong and 
consistent evidence exists to suggest that histamine (HA), acting via H(1) and/or H(3) 
receptors has a pivotal role in the regulation of sleep-wake cycle. Administration of 
histamine or H(1) receptor agonists induces  wakefulness, whereas administration of 
H(1) receptor antagonists promotes sleep. The activation of H(3) receptor reduces 
histamine release and promotes sleep. Conversely, the blockade of H(3) receptor 
promotes wakefulness. The histaminergic neurons display maximal activity during 
the state of high vigilance, and cease their activity during NREMS and REMS. The 
cerebrospinal levels of histamine are reduced in diseased states where 
hypersomnolence is a major symptom. HA-deficient l-histidine decarboxylase 
knockout (HDC KO) mice display sleep fragmentation and increased REM sleep 
during the light period along with profound wakefulness deficit at dark onset, and in a 
novel environment. These studies strongly implicate the critical role of histaminergic 
neurons of the TMN in the maintenance of high vigilance state during wakefulness 
(Thakkar 2011). 
Anaclet et al. studied the behavioral and sleep-wake phenotypes of histidine-
decarboxylase (HDC, HA-synthesizing enzyme) (-/-) mice. HDC-KO mice showed 
sleep fragmentation and increased REMS, similarly to HCRT-KO narcoleptic mice.  
On the contrary, only HCRT-KO mice, but not HDC-KO mice, displayed a complete 
narcolepsy phenotype and deficient W when faced with motor challenges. In 
particular, when placed on a wheel, wild-type (WT), but not littermate HCRT-KO 
- 97 - 
 
mice, voluntarily spent their time turning it and as a result, remained highly awake; 
this was accompanied by dense c-fos (marker of neuronal activity) expression in 
many areas of their brain, including HCRT neurons in the dorsolateral hypothalamus. 
This was evident from the fact that intraventricular infusion of HCRT-1 restored their 
W amount and motor performance (Anaclet 2009). These data indicate that HCRT, 
but not HA, promotes W through enhanced locomotion and suggest that HA and 
HCRT neurons exert a distinct, but complementary and synergistic control of W; the 
neuropeptide is more involved in its behavioral aspects, whereas the amine is mainly 
responsible for its qualitative cognitive aspects and cortical EEG activation. 
Moreover, the activation of central nervous histamine receptors is involved in 
cardiovascular regulation (Suzuki 2005), with different effects on blood pressure and 
heart rate, mediated by different receptor mechanisms.  
It would be interesting to compare the sleep-dependent cardiovascular phenotype of 
HCRT knockout mice, HDC knockout mice and double HCRT/HDC knockout mice 
in order to establish the effect of the interaction between hypocretin and histamine on 
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9.1 Mouse colony management 
Mouse colonies were maintained in the facilities of the Department of Human and 
General Physiology at the University of Bologna, Italy.  
Mice were kept on a light-dark cycle of 12-hour periods with ambient temperature set 
at 25°C and free access to water and food (4RF21 diet, Mucedola, Settimo Milanese, 
Italy). 
Founder mice were generously provided by Prof. E. Mignot (Stanford University, 
USA) and consisted of the following individuals: 1 male and 2 female mice which 
were hemizygous for the HCRT-ataxin3 transgene and fully congenic (12 generations 
of backcrossing) to C57Bl/6J. The colony was expanded in order to perform the 
experiments recently published (Bastianini 2011a; Bastianini 2011b). Founder TG 
mice were first backcrossed once to C57Bl/6J female mice, purchased from Charles 
River, (Calco, Italy) and then maintained by hemizygote X wild-type mating. 
Animals were studied in an inbred background. Inbreeding is the process of breeding 
closely-related individuals for sequential generations and results in alleles throughout 
the genome fixed in homozygosity. A fully inbred strain is one that has undergone 
enough generations of inbreeding that it is mathematically predicted to have 100% 
homozygous genome. Thus, all members of an inbred strain are considered 
essentially genetically identical (Berry 2007). 
Two possible mating schemes were used to expand the colony: the sibling system, in 
which 1 male was mated with a female, and harem mating or trio, in which multiple 
female were mated with a single male. This system increases male reproductive 
performances.  
TG mice were always crossed with wild-type mice in order to avoid the birth of 
homozygous TG mice. All the mice were fully congenic to C57Bl/6J, with a genomic 
homology of  99,9%, because they were within the 10th generation of the sibling 
system and no substrain was created. Colonies separated by more than 20 generations 
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from the progenitor strain are considered to be genetically distinct (Berry 2007). The 
average litter size for the TG colony was 5.0 ± 0.4. 
In order to obtain hTG, male mice, hemizygous for the HCRT-ataxin3 transgene and 
congenic to C57Bl/6J (13 generations of backcrossing) were crossed with female 
(C57Bl/6J × DBA/2J)F1 hybrid mice (strain B6D2F1/J). C57Bl/6J mice and 
B6D2F1/J mice were purchased from Charles River, (Calco, Italy). Hybrid female 
mice had a mixed genetic background, carrying 50% of the DNA of C57Bl/6J and 
50% of DBA/2J strain. Thus, F2 mice had 75% of DNA coming from C57Bl/6J strain 
and 25% DNA of DBA/2J strain. Hybrid mice resulted as more resistant to diseases 
and this characteristic is known as hybrid vigor. This is why the average litter size for 
the hTG colony was 7.4 ± 0.5. 
After a female got pregnant, male mice were removed from the breeding cage. 
Pregnant females were left alone or with other pregnant females in order to promote 
the cross-fostering of offspring and thus improve litter size. 
Male mice were bred until they reached 50 weeks of age, females until 40 weeks of 
age. Usually, reproductive performance begins to decrease in mice older than 6 or 7 
months (Berry 2007). 
When newborn mice were 25 days old, they were separated from their mothers and 
males were separated from females to avoid further breeding. Then, they were 
anaesthetized, so that their left ears could be marked with a puncher and a small tail 
biopsy, to be used for genotyping, could be obtained. After the genotyping procedure, 
mice were again anaesthetized to mark their right ear, following the legend in Figure 
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9.2 Genotyping procedure 
Mouse genotype was assessed in the facilities of the Centre for Applied Biomedical 
Research - CRBA, S. Orsola University Hospital, Bologna, Italy. DNA was extracted 
from bioptic tissue, amplified by polymerase chain reaction and resolved by gel 
electrophoresis.  
ü DNA extraction from tail biopsies 
Tail biopsies, with a length of about 0.5 cm, were put in eppendorf tubes and stored at -80°C. To 
extract DNA, a protease (proteinase K 10 mg/ml, Sigma Aldrich, Italia), was added to the tail 
biopsies, to digest all the native proteins. The material was incubated overnight in a thermomixer at 
56°C in orbital shaking. In the morning, at the end of the digestion, DNA was precipitated using the 
salting-out technique and dissolved in TE buffer (Tris Hcl 1 M, EDTA 0.5M in water). 
ü Polymerase chain reaction 
Subsequently, a range of DNA between 10-100ng was amplified with a polymerase chain reaction. 
The reaction solution was composed of: buffer 1X, deoxinucleotides (0.2 mM), MgCl (1.5 mM), 
Taq Polymerase (0.02 U/µl, Promega, Italy), and specific primers (0.5 µM, Sigma Aldrich, Italy).  
Primer sequences used for hWT and hTG were:  
5’-TCACCCCCTTGGGATAGCCCTTCC-3’(WT, allele 5’) 
5’-GACGACGGCCTCAGACTTCTTGGG-3’(WT, allele 3’) 
5’-GCAGCGGCCATTCCTTGG-3’(transgene, 5’) 
5’-AAGTCGACGGTGTCTGGCGCTCAGGGTG-3’(transgene, 3’) 
ü Gel electophoresis 
At the end of the PCR reaction, PCR products were loaded in an agarose gel (2%) and resolved by 
gel electrophoresis. DNA bands were visible because of the Etidium Bromide (EtBr) added to the 
gel during its preparation. EtBr is fluorescent under UV light when intercalated into the major 
grooves of DNA. By running DNA through an EtBr-treated gel and visualizing it with UV light, 
any band containing more than ~20ng DNA becomes distinctly visible. The products of 
amplification reaction of hTG mice samples were visualized as two bands: a small one, 250 base 
pairs (bp) long (transgene allele) and another, 400 bp long (wild-type allele), whereas hWT showed 
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only one 400 bp long band (wild-type allele), as results from Figure 3. The size of unknown DNA 
molecules was estimated through the comparison with a DNA ladder, (Sigma Aldrich), a solution 
of DNA molecules of different lengths that separate during gel electrophoresis. 
 
9.3 qRT-PCR 
A preliminary experiment was performed on 2 hTG mice and 1 hWT to verify the 
expression of three genes of interest, GAPDH, prepro-HCRT and Ataxin-3 by 
quantifying the mRNA in their brains. The brain of each animal was removed and 
immediately dissected to separate the diencephalon from the rest, then frozen at -
80°C. Total m-RNA was extracted using a phenol-chloroform solution (Tri-Reagent, 
Applied Biosystem), following the manufacturer’s protocol. The RNA obtained was 
dissolved in sterile water, in a previously determined volume, in order to obtain a 
concentration in the range between 500 and 1000ng/µl. The concentration was 
verified by testing UV absorption with nanodrop 2000. The extracted RNA was 
checked for its quality, taking into consideration both purity (absence of protein and 
DNA contamination, absence of inhibitors) and integrity (Nolan 2006). Nanodrop 
allowed for the identification of the contamination on the part of any solvent or 
protein, through the analysis of the A260/A280 ratio. Furthermore, to assess the 
quality of extracted RNA, 1µl of RNA was loaded in a 1% gel and after a gel 
electrophoresis run, three bands were visualized corresponding to the major quantity 
of RNA, the 3 subunits of the ribosomal RNA. The presence of other bands indicated 
that RNA was degraded. After the extraction, an aliquot of RNA was purified to 
eliminate genomic DNA by enzymatic digestion with DNAsi I (Sigma Aldrich, Italy). 
For each sample, 2 aliquots were purified, in order to use one for the retro-
transcription and the other as a control. After verification of sample purity and 
quality, RNA was converted in c-DNA using a retro-transcriptase (High capacity 
RNA-to-c-DNA kit, Applied Biosystem). 1µg of RNA was retro-transcripted in 1 µg 
of DNA. One tube was retro-transcripted; in the other, all the reagents were added, 
except for the retro-transcriptase. In order to assess the retro-transcription, c-DNA 
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and control samples were amplified with a PCR reaction for a control gene 
(GAPDH). The retro-transcripted tube showed an amplification, which was absent in 
the control. After the retrotranscription, qRT-PCR was performed with the Sybr green 
method (Go Taq q-PCR, Promega). The Sybr green, a green dye, binds to double-
stranded (ds) DNA, thus providing a fluorescent signal that reflects the amount of 
double strand DNA products generated during PCR. The direct fluorescence was 
revealed by a special thermocycler Iq5, Biorad.  
Primers must be chosen carefully in order to avoid non-specific amplification. When 
designing gene-specific real-time PCR primers, it is important to keep in mind the 
fact that amplicon length should be approximately 80-250 bp. In general, primers 
should be 18-24 nucleotides in length and should have comparable melting 
temperatures (within 5°C). Moreover, primers should be specific for the target 
sequence and be free of internal secondary structure. If possible, it is preferable to 
design primers that anneal on both sides of an intron to avoid the amplification of 
genomic DNA (Bustin 2007). In this experiment, the ENSEMBL database 
(www.ensembl.org) was used to custom design primers.  
To confirm the specificity of chosen primers (primers should recognize only the 
target of interest), the sequences were tested in silico for any unspecific alignment 
either in the human or mouse genome (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Primers were purchased from Sigma-Aldrich, Italy, as a powder, and then 
reconstituted in sterile water. 
Primers chosen for the experiments were: 
5’-CGTGCCGCCTGGAGAAACC-3’ (GAPDH, 5’) 
5’-TGGAAGAGTGGGAGTTGCTGTTG-3’ (GAPDH, 3’) 
5’-ACGCTGCTGCTGCTGCTAC-3’ (prepro-HCRT, 5’) 
5’-CCGCCGCTTTCCCAGAGTC-3’ (prepro-HCRT, 3’) 
5’-GGGACCTATCAGGACAGAGTTCAC-3’ (Ataxin-3, 5’) 
5’-AGCATCACCTAGATCACTCCCAAG-3’ (Ataxin-3, 3’)  
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Amplification efficiencies of these primers were tested with calibration curves. The 
following efficiencies were obtained: 
GAPDH efficiency = 92% 
Prepro-HCRT efficiency = 83% 
ATAXIN3 efficiency = 82% 
For every diencephalon the 3 genes were tested in triplicate. At the end of the qRT-
PCR a further test was carried out on PCR products. For every tube, a melting curve 
was created in order to evaluate the presence of nonspecific products of 
amplification. A melting curve charts the change in fluorescence observed when 
double-stranded DNA (dsDNA) with incorporated dye molecules dissociates, or 
“melts” into single strand DNA (ssDNA) as the temperature of the reaction is raised. 
These curves are based on gradual increments (0.5°C) of temperature. If nonspecific 
products are present more than one melting value will be found in each well. Only 
one melting value for every tube was found in my samples and these values were 












































































Figure 1. Example of scoring window. The automatic scoring procedure 
automatically classified the behavioral state (top of this window: W, wakefulness; 
NREMS, NREM sleep; REMS, REM sleep) for each 4-s epoch;  this classification is 

































Figure 2. Three dimentional (on the left) and bidimendional (on the right) graphs 
showing all the 4s epochs recorded in a single mice. X-axis, reports the root mean 
square of EMG; Y-axis reports θ/δ EEG ratio; Z-axis reports the density of epochs. 
The color scale used on z-axis reflects the number of epochs for each couple of x-y 
coordinates, with blue color indicating a low number, and red color indicating a high 
number.  
Wakefulness (W) is characterized by high EMG tone; NREM sleep (NREMS) is 
characterized by low EMG tone and low theta/delta (θ/δ) EEG ratio; REM sleep 
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Figure 3 
 












Figure 3. Example of visualization of the results of PCR (polymerase chain reaction) 
with gel electrophoresis. DNA ladder is loaded in the first well and after DNA 
migration, it is possible to visualize different bands (50 base pairs). Samples of two 
transgenic mice (hTG) are loaded in the second and third wells whereas samples of 
two wild-type control mice (hWT ) are loaded in the last two wells. The upper band is 
250 base pairs long (transgene allele), whereas the bottom one is 400 base pairs long 



















































Figure 4. Cerebral HCRT-1 concentration obtained in 4 transgenic mice ((hTG, red 
bars) and 5 wild-type control mice (hWT, blue bars) determined with a fluorescent 
immunoassay kit (FEK 003-30, Phoenix Pharm. Inc., Burlingame, CA, USA). Data 







































Figure 5. Relative expression of genes of interest (Ataxin3 and prepro-HCRT) 
compared to an housekeeping gene (GAPDH) in 3 young hybrid mice (1 wild-type 
control mouse, hWT, and 2 transgenic mice, hTG). hWT mouse showed high 
expression of prepro-HCRT and complete absence of Ataxin3. Both hTG1 and hTG2 
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Figure 6. Mean blood pressure values in transgenic mice (hTG, n=11) and wild-type 
control mice (hWT, n=12) in wakefulness, non rapid-eye movement sleep (NREMS) 
and in rapid-eye-movement sleep (REMS) at different ambient temperature (20°C, 
25°C, 30°C). Error bars represent SEM. ANOVA showed a significant interaction 
effect between wake-sleep state and Ta on MBP (p<0,001), and significant main 
effects of wake-sleep states and Ta on MBP (p<0,001). 
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Figure 7. Heart rate (HR) values in transgenic mice (hTG, n=11) and wild-type 
control mice (hWT, n=12) in wakefulness, non rapid-eye movement sleep (NREMS) 
and in rapid-eye-movement sleep (REMS) at different ambient temperature (20°C, 
25°C, 30°C). Error bars represent SEM. ANOVA showed a significant interaction 
effect between wake-sleep state and Ta on HR (p<0,001), and significant main effects 
of W-S states and Ta on HR (p<0,001). 



























































Figure 8. Differences in mean blood pressure (MBP) (upper graph) and heart rate 
(HR)  (bottom graph) between the exposure at 20°C and 30°C in transgenic mice 
(hTG, n=11) and wild-type control mice (hWT, n=12) during wakefulness, non-
rapid-eye-movement sleep (NREMS) and rapid-eye-movement sleep (REMS). Error 
































































































Figure 9. Differences in mean blood pressure (MBP) (on the left) and heart rate (HR) 
(on the right) between wakefulness and non-rapid-eye-movement sleep (NREMS) 
and between wakefulness and rapid-eye-movement sleep (REMS) in transgenic mice 
(hTG, n=11) and wild-type control mice (hWT, n=12), at 20°C and 30°C. Error bars 




















































































Figure 10. Cross-correlation function between systolic blood pressure (SBP) and 
heart rate (HR) in wakefulness, non-rapid-eye-movement sleep (NREMS) and rapid-
eye-movement sleep (REMS) in transgenic mice (hTG, n=11) at 20°C and 30°C (red 
and green lines, respectively) and wild-type control mice (hWT, n=12) at 20°C and 
30°C (blue and black lines, respectively). ANOVA showed a significant main effect 
of wake-sleep (W-S) state and ambient temperature (Ta), and an interaction effect 
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Figure 11 
 












Figure 11. Legend of ear punching. Animal in the same cage were identified  making 
a different number of holes in different position on the left ear. 


















State Ta  hTG hWT 
W (%) 
   20°C * 48.9 ± 1.0 47.6 ± 1.3 
30°C 46.5 ± 4.1 40.4 ± 1.5 
NREMS (%) 
20°C 43.2 ± 1.0 45.0 ± 1.5 
30°C 44.8 ± 3.7 50.8 ± 1.4 
REMS (%) 
   20°C * 5.0 ± 0.3 4.8 ± 0.4 


















Table 1. Percentage of wake and sleep states during the recording period: W, 
Wakefulness; NREMS, non rapid-eye-movement sleep; REMS, rapid-eye-movement 
sleep. Values are reported as mean ± SEM in transgenic mice (hTG, n=11) and wild-















 Ta hTG hWT 
n°of W 
(episodes over 24h) 
20°C 214.6 ± 15.7 * 138.3 ± 7.9 
30°C 202.6 ± 13.6 * 143.3 ± 4.2 
n°of NREMS 
(episodes over 24h) 
20°C 478.0 ± 19.7 449.5 ± 25.4 
30°C 414.0 ± 32.1 486.4 ± 23.3 
n°of REMS 
(episodes over 24h) 
20°C 74.3 ± 7.1 66.8 ± 5.3 
30°C 76.6 ± 8.3 71.3 ± 5.8 
W bout duration 
(sec) 
20°C 200.9 ± 14.0 * 300.6 ± 24.2 




20°C 78.5 ± 3.2 89.7 ± 6.9 
30°C 92.5 ± 4.8 91.9 ± 4.8 
REMS bout duration 
(sec) 
20°C 60.6 ± 3.6 61.5 ± 2.3 




20°C 280.1 ± 25.0 * 497.7 ± 42.9 
30°C 376.0 ± 717.2 * 717.2 ± 72.6 












Table 2. Density (number in 24 h) and duration of wake and sleep states episodes: W, 
Wakefulness; NREMS, non rapid-eye-movement sleep; REMS, rapid-eye-movement 
sleep. Values are reported as mean ± SEM in transgenic mice (hTG, n=11) and wild-















Factors MBP HR 
W-S states P<0,001 P<0,001 
Ta P<0,001 P<0,001 
Strain x Ta P=0, 882 P=0,176 
Strain x W-S states P<0,001 P=0,020 
W-S states x Ta P<0,001 P<0,001 




















Table 3. 3-way Analysis of variance (ANOVA) results for mean blood pressure 
(MBP) and heart rate (HR): in red are reported the significant results, whereas non 
















Ta  Mouse Strain 
MBP difference 




hTG 6.4 ± 1.1 
hWT 1.7 ± 0.9 
30°C* 
hTG 12.3 ± 1.4 





















Table 4. Mean blood pressure (MBP) difference between non-rapid-eye movement 
sleep (NREMS) and rapid-eye-movement sleep (REMS) in transgenic mice (hTG, 
n=11) and wild-type control mice (hWT, n=12) at 20°C and 30°C. 
MBP difference between NREMS and REMS is significantly higher at 30°C in both 
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